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Abstract 
 Colorectal cancer is the 3
rd
 most common cancer worldwide and this rate of incidence is 
largely attributable to lifestyle factors such as the diet. A group of plant secondary metabolites 
called flavonoids has been found to exert various anticancer activities in colorectal cancer cell 
lines and is indeed thought to function similarly in vivo. The cell-surface enzymes CD26, CD38, 
and CD73 are present in colorectal cancers and their presence and activities in this context have 
the potential to be modulated by extracellular factors such as dietary flavonoids. The levels of 
CD26 protein in particular have been previously found to increase at the cell surface in HT-29 
colorectal cancer cells following treatment with the flavonoid apigenin. Another extracellular 
factor which may alter the response of cancer cells is cell density. In this work, the role of 
apigenin was investigated first on the mRNA transcription of CD26, CD38, and CD73 in HT-29 
cells cultured to increasing degrees of confluence. CD26 was identified as the most promising 
target because it revealed the greatest degree of mRNA variability. Next, the amount of CD26 
mRNA and protein was quantified in HT-29 cells treated with apigenin and the related 
flavonoids genistein, kaempferol, and luteolin. Finally, the localization of CD26 protein was 
observed in these cells following flavonoid treatment. This investigation showed no consistent 
changes in either mRNA expression or whole cell protein abundance for CD26. However, there 
was a distinct change in cellular localization of CD26 in response to apigenin and genistein and 
this was seen particularly in colorectal cancer cells at low levels of confluence. The relocation of 
the CD26 protein may depend on particular features of the flavonoid structure. Furthermore this 
effect appears be modulated by a change in cell confluence. Therefore this study provides new 
insights with respect to the role of flavonoids in regulating CD26 in colorectal cancer cells. 
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1 Introduction 
1.1 Colon Cancer 
 Each year, over 1.2 million people worldwide are diagnosed with colon cancer and more 
than 600,000 die from this disease; it is the 3
rd
 most common cancer and the 4
th
 deadliest.1, 2 
Indeed, it accounts for 10% of all cancer-related mortality in Western countries.
2
 Colon cancer is 
more common amongst older men and other risk factors include a family history of colon cancer, 
the excessive consumption of alcohol and processed meat, obesity, diabetes, smoking, low 
physical activity, and inflammatory bowel disease.1, 2 It is particularly concerning that countries 
with a historically low prevalence of colon cancer are now experiencing an increase in its 
incidence.
1
 This parallels their economic development and their consequent adoption of a 
Western lifestyle which predisposes them to this disease.
1
 Some studies suggest that roughly 
37% of colon cancers in women and 71% of those in men are preventable given a shift in 
lifestyle factors.
3, 4
  
1.2 The Dietary Connection 
In addition to exercise, hormone replacement therapy, aspirin use, and the surgical 
removal of precancerous lesions, some studies suggest that a dietary change is a means by which 
to prevent the onset of colon cancer.
1
 Indeed, epidemiological studies demonstrate that fruit and 
vegetable intake are inversely associated with colon cancer risk.
2, 5
 The diet is clearly important 
when one considers the direct and continuous interactions between dietary constituents and the 
colonic epithelium. Furthermore, the effects of dietary compounds on colon cancer cells may 
also exist in other cancers if they were to be exposed after systemic uptake. A subject of growing 
interest in the fields of colon cancer prevention and therapy is a group of plant secondary 
metabolites called flavonoids which share a 15-carbon 3-ringed structure.
6, 7
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1.3 Flavonoids 
1.3.1 Apigenin 
Apigenin (4′,5,7-trihydroxyflavone; Figure 1.1) is a flavonoid commonly found in the 
leaves of parsley and chamomile flowers.
8
  
 
Figure 1.1. The structure of apigenin.
9
  
 
Apigenin is known to inhibit cell proliferation and cell cycle progression in oral 
squamous, esophageal, pancreatic, gastric, and colorectal cancer cell populations (its targets in 
vitro are presented below in Tables 1.1, 1.2, and 1.3 found in Sections 1.3.7, 1.3.8, and 1.3.9 
respectively).
10-14
 Lefort and Blay also showed that apigenin induced the upregulation of a cell-
surface enzyme called CD26 and increased its anticancer functions.
15
 The threshold 
concentrations required for these effects range between 1-10μM for a 48h treatment which is 
more readily achievable in vivo than the concentrations required to inhibit cell growth or induce 
apoptosis.
15
 Furthermore, apigenin was also shown to potentiate the ability of the 
chemotherapeutic drug irinotecan to upregulate the CD26 protein by more than 30-fold.
15
  
1.3.2 Genistein 
Genistein (4',5,7-trihydroxyisoflavone; Figure 1.2) is an isomer of apigenin and can be 
found in soybeans.
16
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Figure 1.2. The structure of genistein.
17
  
 
Genistein is one of the most common flavonoids in nature and consequently one of the 
most widely studied.
16
 It has been found to inhibit cell growth and induce apoptosis in leukemias 
and cancers of the breast, prostate, colon, liver, lung, ovary, bladder, and brain.
16
 Due to the 
ubiquity of soy in Asian diets and the status of genistein as the principal anticancer component of 
soy (its targets in vitro are presented below in Tables 1.1, 1.2, and 1.3), the consumption of 
dietary genistein is suspected to partly account for the differences in tumor incidence between 
Asian and Western countries.
18, 19
 Whilst epidemiologic data on intake of purified genistein is 
understandably scarce, several studies have suggested that dietary soy intake reduces the risk of 
colorectal cancer in humans.
20-23
   
1.3.3 Kaempferol 
Kaempferol (3,4′,5,7-tetrahydroxyflavone; Figure 1.3) is another flavonoid similar in 
structure to apigenin and luteolin. Kaempferol can be found in broccoli, cabbage, tomatoes, and 
strawberries.
24
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Figure 1.3. The structure of kaempferol.
25
 
Like the other flavonoids, kaempferol can induce cell cycle arrest and apoptosis in cancer 
cells (its targets in vitro are presented below in Tables 1.1, 1.2, and 1.3). Being similar in 
molecular weight and having similar general biological effects to apigenin, it can nonetheless 
serve as a control substance in studies of CD26 due to its confirmed inability to affect CD26 
protein levels or enzyme function within colon cancer cells.
15, 26
  
1.3.4 Luteolin 
Luteolin (3′,4′,5,7-tetrahydroxyflavone; Figure 1.4) is the primary metabolite of apigenin 
and as a result its activity within colon epithelial cells is a natural point of interest. Luteolin can 
be found in celery and in green peppers.
27
 
 
Figure 1.4. The structure of luteolin.
28
 Luteolin has also been shown to be associated with 
cell proliferation, metastasis, and the induction of apoptosis within cancer cells (its targets in 
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vitro are presented below in Tables 1.1, 1.2, and 1.3). Although it can be isolated from blood 
plasma following a meal, studies have yet to determine whether the consumption of luteolin has 
a measurable effect on human cancers.
27
 
1.3.5 Flavonoids Crossing the Intestinal Epithelium and Entering the Plasma Membrane 
Flavonoids are usually found and consumed in the glycoside form which is more water 
soluble than their aglycone form.
29
 Once they reach the small intestine, sodium-dependent 
glucose transporter 1 (SGLT1) can transfer the glycosides across the apical surface of the 
epithelial cells.
30
 Flavonoid glycosides can also pass through the epithelium using the glucose 
transporters GLUT-1 and GLUT-2.
29
 Cytosolic β-glucosidases can then cleave off this sugar 
moiety after which the flavonoid agylcone can remain within the cell or enter the systemic 
circulation.
30
 However, this method of absorption is rendered inefficient by the multidrug 
resistance-associated protein 2 (MRP2) which can export the flavonoid glycoside back into the 
lumen of the small intestine.
30
 Within the lumens of both the small and large intestines, brush 
border β-glucosidases can cleave the flavonoid aglycone from the glycosylated form after which 
it can be absorbed by the epithelial cells.
30
 Once the aglycone reaches the liver, it can be 
glucuronidated, sulfated, or undergo oxidative metabolism prior to excretion.
30
  
Flavonoid aglycones can also directly enter plasma membranes because they are 
hydrophobic and therefore tend to accumulate in membranes, especially lipid rafts.
29
 The 
structure of flavonoids determines how extensively they penetrate through the plasma 
membrane.
31
 The polar phosphate groups of the membrane make hydrogen bonds with hydroxyl 
groups, sugar moieties, and sulfate groups.
31
 This may also affect the orientation of the flavonoid 
and whether it can interact with lipid rafts. Flavonoids may affect the membrane fluidity of 
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cancer cells to different degrees and this phenotypic effect has been hypothesized to result in 
different effects on the metastatic properties of cancer cells in vitro.
32-34
 
1.3.6 The Complexity of Molecular Signaling Due to Flavonoids   
Flavonoids modulate a wide variety of signaling pathways within the cytosol of the cell. 
These govern critical cell functions such as metabolism, cell growth and progression through the 
cell cycle, apoptosis, autophagy, cell differentiation, and cancer cell metastasis.
11, 35-50
  The 
effects of the flavonoids discussed above on these important cell processes within cancer cells 
have been summarized in Tables 1.1, 1.2, and 1.3. The signaling due to flavonoids can be 
complex and initiate branching pathways of regulation. For example, one group found that 
apigenin binds to ribosomal protein S9, inhibiting its activity in both HT-29 and SW620 colon 
carcinoma cells.
51
 In turn this may affect the transcription of a number of proteins downstream 
and it raises the possibility that other flavonoids may have the same effect. 
1.3.7 Flavonoids and Cancer Cell Cycle Arrest/ Apoptosis 
 Cancer cells have altered cell cycle dynamics: they experience both an increase in 
positive growth signaling and a decrease in those signaling pathways which would normally 
prevent unchecked growth.
52
 Cyclins and cyclin-dependent kinases (CDK) are key regulators of 
cell division, each having a different role depending on the stage of the cell cycle as well as the 
type of cell in question.
52, 53
 They generally form complexes to carry out their functions, which 
are counteracted by CDK inhibitors such as p21.
53
 Apoptosis is a controlled death process 
normally used to remove unwanted cells from an organism.
54
 It can be triggered by a number of 
pathways, all of which result in the activation of caspase proteins.
54
 Caspases are proteases that, 
when activated, help dismantle a wide variety of cellular structures.
54
 Apoptotic events are 
further modulated by anti-apoptotic proteins such as B-cell lymphoma-2 (BCL-2) and BCL-XL 
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and pro-apoptotic proteins such as BAX or BAD.
54
 The effects of flavonoids on cancer cell cycle 
arrest and apoptosis and the overall significance of these effects are summarized in Table 1.1 
below. 
Table 1.1. The effects of flavonoid treatment on cell cycle arrest or apoptosis.  
Cell Line Flavonoid 
Treatment 
Effect Significance Citation 
Cell Type 
T24 40μM 
Apigenin 
 ↓ Bcl-xl 
 ↓ Bcl-2 
 ↑ Bax 
 ↑ Bad 
 ↑ Caspase-3 
 Apoptosis via the activation of 
caspase 3, the downregulation 
of the anti-apoptotic proteins 
Bcl-xl and Bcl-2, and the 
upregulation of the pro-
apoptotic proteins Bax and Bad  
35
 
Bladder 
Carcinoma 
HepG2 40μM 
Apigenin 
 ↑ Bax 
 ↓ Bcl-2 
 ↑ Cleaved PARP 
 ↑ Cleaved 
caspase-9 
 Inhibition of autophagy further 
increased the expression of the 
apoptotic proteins Bax, cleaved 
PARP, and cleaved caspase 9 
 Inhibition of autophagy further 
decreased the expression of the 
anti-apoptotic protein Bcl-2  
36
 
Liver 
Carcinoma 
HCT116 50μM 
Apigenin 
 ↓ Pro-caspase 8 
 ↓ Pro-caspase 9 
 ↓ Pro-caspase 3 
 ↑ p21waf1 
 ↑ p53 
 ↓ Cdc25c 
 ↓ CDK1  
 ↓ Cyclin B1 
 Cell cycle arrest in G2/M phase 
via upregulation of  p53 and 
p21
waf1
 and downregulation of 
Cdc25c, CDK1, and cyclin B1
 
 
 Apoptosis via caspase protein 
activation (cleavage of pro-
caspases 3, 8, and 9)  
37
 
Colorectal 
Carcinoma 
MDA-MB-
231 
50μM 
Apigenin 
 ↓ Cyclin A 
 ↓ Cyclin B 
 ↓ CDK1 
 ↑ p21waf1 
 Cell cycle arrest in G2/M phase 
via downregulation of cyclin 
A, cyclin B, and cyclin-
dependent kinase-1 (CDK1), as 
well as upregulation of p21
waf1
  
38
 
Breast 
Carcinoma 
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KYSE-510 80μM 
Apigenin 
 ↑ p63 
 ↑ p73 
 ↓ p53 
 ↑ Cleaved 
caspase 3 
 ↑ p21waf1 
 ↓ Cyclin B1 
 Upregulation of p63 and p73 
protein induced p21
waf1
 
transcription and cleavage of 
caspase 3 
 Cell cycle arrest in G2/M phase 
via p21
waf1
 upregulation and 
cyclin B1 downregulation 
 Apoptosis via cleavage of 
caspase 3 
11
 
Esophageal 
Carcinoma 
HT-29 200μM 
Genistein 
 ↑ Caspase-3 
 ↑ Caspase-8 
 ↑ Bax 
 ↓ Bcl-2 
 Apoptosis via the activation of 
caspase 3 and caspase 8, the 
downregulation of the anti-
apoptotic protein Bcl-2, and the 
upregulation of the pro-
apoptotic protein Bax  
39
 
Colorectal 
Carcinoma 
A2780/ 
CP70 
40μM 
Kaempferol 
 ↑ Phosphorylated 
Chk2 
 ↑ Phosphorylated 
Cdc25c 
 ↑ p21 
 ↑ Phosphorylated 
CDK1 
 ↑ DR5 
 ↑ Fas 
 Increased 
enzyme activity 
of caspase-3/7, 
caspase-8, and 
caspase-9 
 Cell cycle arrest in G2/M phase 
via Chk2/Cdc25C/Cdc2 and 
Chk2/p21/Cdc2 pathways 
 Activation of Chk2 by 
kaempferol in turn inactivated 
the G2/M phase- associated 
proteins Cdc25C and Cdc2 
 Apoptosis via the 
DR5/FADD/Caspase 8 
pathway 
 Upregulation of DR5 increased 
the activation of Caspase-3/7 
and Caspase-8 
40
 
Ovarian 
Carcinoma 
HT-29 60μM 
Kaempferol 
 ↓ CDK2 
 ↓ CDK4 
 ↓ Cyclin D1 
 ↓ Cyclin E 
 ↓ Cyclin A 
 ↓ Cyclin B1 
 ↓ Cdc25C 
 Cell cycle arrest in G1 phase 
via downregulation of cyclin 
D1, E, A, and CDK2/4 
 Cell cycle arrest in G2/M phase 
via downregulation of Cdc25C 
and cyclin B1 
 
41
 
Colorectal 
Carcinoma 
KYSE-510 80μM 
Luteolin 
 ↑ p63 
 ↑ p73 
 ↓ p53 
 ↑ Cleaved 
caspase 9 
 Upregulation of p63 and p73 
protein induced p21
waf1
 
transcription and cleavage of 
caspase 3 and caspase 9 
 Luteolin found to be more 
11
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Esophageal 
Carcinoma 
 ↑ Cleaved 
caspase 3 
 ↑ p21waf1 
 ↓ Cyclin B1 
cytotoxic than apigenin 
 Cell cycle arrest in G2/M phase 
via p21
waf1
 upregulation and 
cyclin B1 downregulation 
 Apoptosis via cleavage of 
caspase 3 and caspase 9 
The symbol “↑” indicates an increase in whole cell protein (or the indicated activity), or 
upregulation, whereas the symbol “↓” indicates a decrease in whole cell protein (or the activity), 
or downregulation. 
 Flavonoids are able to induce cell cycle arrest and apoptosis in many cancer cell lines. 
Cell cycle arrest can be induced at the G1/S checkpoint through the downregulation of cyclins 
D1, E, and A as well as the downregulation of the cyclin-dependent kinases CDK2 and CDK4.
41
 
More frequently, however, the cell cycle is arrested at the G2/M checkpoint by the 
downregulation of cyclin B1 and CDK1, and the altered expression of the cyclin-dependent 
kinase regulating proteins Cdc25c, p21, and p53.
11, 37, 38, 40, 41
 Flavonoids can also trigger 
apoptosis through the increased expression of the apoptotic proteins Bax and Bad, the decreased 
expression of the anti-apoptotic proteins Bcl-2 and Bcl-xl, and the activation of Caspase-3, -7, -8, 
and -9.
11, 35-37, 39, 40
 
1.3.8 Flavonoids and the PI3K/Akt/mTOR Pathway  
 The PI3K/Akt/mTOR pathway is involved with a broad range of upstream regulators and 
downstream targets; therefore it affects a broad range of cellular processes including cell 
survival, cell cycle progression, apoptosis, autophagy, metabolism, and cancer cell metastasis.
55
 
It may also be able to modulate the presence of cell surface proteins like CD26, CD38, and 
CD73 by altering the activity of a number of transcription factors which regulate gene 
expression.
55
 Various components of this pathway, including p-85α, Akt1, Akt2, p-mTOR and p-
p70S6K, have been found in colorectal cancer cells compared with normal colonic tissue 
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belonging to the same patients.
56
 The effects of flavonoids on the PI3K/Akt/mTOR pathway and 
the overall significance of these effects are summarized in Table 1.2 below. 
Table 1.2. The effects of flavonoid treatment on the PI3K/Akt/mTOR pathway.  
Cell Line Flavonoid 
Treatment 
Effect Significance Citation 
Cell Type 
HepG2 20μM 
Apigenin 
 ↓ Phosphorylated 
PI3K 
 ↓ Phosphorylated 
Akt 
 ↓ Phosphorylated 
mTOR 
 ↑ LC3-I 
 ↑ LC3-II 
 Accumulation of LC3-I and 
LC3-II proteins indicate that 
autophagy has been triggered.  
 Autophagy was found to be a 
protective response to prevent 
apoptosis. 
 Apigenin’s anti-proliferative 
and apoptotic effects were 
dependent on the inhibition of 
the PI3K/Akt/mTOR signaling 
pathway.   
36
 
Liver 
Carcinoma 
HCT-116 50μM 
Apigenin 
 ↓ Phosphorylated 
Akt but not total 
Akt 
 ↓ Phosphorylated 
p70 S6 kinase 
 ↓ Phosphorylated 
4E-BP1 
 Inhibition of Akt/mTOR 
signaling pathway leads to 
autophagosome formation 
 Apigenin induces β-catenin 
degradation in lysosomes 
which inhibits Wnt/ β-catenin 
signaling 
42
 
Colorectal 
Carcinoma 
HEK293 5μM 
Genistein 
 ↓ Phosphorylated 
Akt 
 Resulted in decrease in 
phosphorylation of GSK-3β 
43
 
Human 
Embryonic 
Kidney  
HeLa 25μM 
Genistein 
 ↓ Phosphorylated 
Akt 
 ↓ Phosphorylated 
p70 S6 kinase 
 ↓ Phosphorylated 
mTOR 
 
 Genistein helped decrease cell 
proliferation  
44
 
Cervical 
Carcinoma 
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HEK293 10μM 
Kaempferol 
 ↑ Phosphorylated 
Akt 
 No effect on GSK-3β 
phosphorylation 
43
 
Human 
Embryonic 
Kidney 
SK-HEP-1 75μM 
Kaempferol 
 ↓ Phosphorylated 
Akt 
 ↓ Phosphorylated 
mTOR 
 ↑ LC3-I 
 ↑ LC3-II 
 Inhibition of Akt/mTOR 
signaling pathway leads to 
autophagosome formation 
 Accumulation of LC3-I and LC3-
II proteins indicate that 
autophagy has been triggered.  
45
 
Liver 
Carcinoma 
U251MG & 
U87MG 
20μM 
Luteolin 
 ↓ Phosphorylated 
IGF-1R 
 ↓ Phosphorylated 
Akt 
 ↓ Phosphorylated 
mTOR 
 ↓ MMP-9 
 ↓ MMP-2 
 ↑ TIMP-1 
 ↑ TIMP-2 
 Reduction in phosphorylated 
insulin-like growth factor 1 
receptor (IGF-1R) led to 
downstream reduction in 
phosphorylated Akt and mTOR 
 Reduction in phosphorylated 
Akt and mTOR led to 
downregulation of 
metalloproteinase (MMP)-2 
and MMP-9 and upregulation 
of tissue inhibitor of 
metalloproteinase (TIMP)-1 
and TIMP-2  
 This resulted in the inhibition 
of cell migration  
46
 
Glioblasto
ma 
JAR & 
JEG-3 
20μM 
Luteolin 
 ↓ Phosphorylated 
Akt 
 ↓ Phosphorylated 
p70 S6 kinase 
 ↓ Phosphorylated 
mTOR 
 
 Inhibition of PI3K/Akt/MTOR 
signaling pathway led to 
inhibition of cell proliferation 
 Downregulation of mTOR 
resulted in a decrease in 
downstream gene transcription 
47
 
Placental 
Carcinoma  
The symbol “↑” indicates an increase in whole cell protein (or the indicated activity), or 
upregulation, whereas the symbol “↓” indicates a decrease in whole cell protein (or the activity), 
or downregulation. 
Flavonoids can affect the PI3K/Akt/mTOR pathway at several points. Flavonoid 
treatment can prevent the phosphorylation and activation of PI3K, which subsequently inhibits 
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the phosphorylation and activation of the downstream proteins Akt and mTOR.
36
 Alternatively, 
the inactivation of Akt and mTOR can be induced by the inactivation of IGF-1R.
46
 A reduction 
in mTOR activation results in the decreased phosphorylation of p70 s6 kinase, a transcription 
factor, and consequently reduced gene transcription and cell proliferation.
42, 44, 47
 The inhibition 
of Akt/mTOR signalling can also trigger autophagic processes as evidenced by increases in the 
protein levels of LC3-I and LC3-II.
36, 45
 Additionally, Akt/mTOR inhibition can also 
downregulate the metalloproteinases MMP-2 and MMP-9 and upregulate the metalloproteinase 
inhibitors TIMP-1 and TIMP-2, resulting in decreased cell migration.
46
 
1.3.9 Flavonoids and the Wnt Pathway 
 The Wnt signaling pathway controls embryonic development and regulates functions 
such as cell proliferation, cell survival, and cell differentiation.
57
 The Wnt signaling pathway is 
one that is often found to be mutated in cancers.
58
 For example, colon cancers have been noted to 
have accumulated nuclear β-catenin as well as mutations in APC, Axin 1, and Axin 2.57 Indeed, 
mutations in the Wnt pathway are the cause of 90% of all colon cancers.
59
 Although complex, 
these mutations have been generalized as a general upregulation of oncogenes and 
downregulation of tumor suppressors found in the Wnt pathway.
58
 Additionally, several 
transcription factors are modulated by the Wnt pathway and in turn these could affect the 
production of cell-surface proteins such as CD26, CD38, and CD73.
59
 The effects of flavonoids 
on the Wnt pathway and the overall significance of these effects are summarized in Table 1.3 
below.  
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Table 1.3. The effects of flavonoid treatment on the Wnt pathway.  
Cell Line Flavonoid 
Treatment 
Effect Significance Citation 
Cell Type 
SW480 20μM 
Apigenin 
 ↓ Nuclear but not 
cytosolic β-
catenin 
 ↓ Axin2  
 ↓ C-myc  
 ↓ Cyclin D1 
 Prevented entry of β-catenin 
into the cell nucleus 
 Decreased the expression of the 
Wnt downstream target genes 
Axin2, C-myc, Cyclin D1 
48
 
Colorectal 
Carcinoma 
HCT116 50μM 
Apigenin 
 ↓ Cytoplasmic 
and nuclear β-
catenin 
 ↓ Cyclin D1  
 ↓ c-Myc  
 ↓ Axin2 
 Induction of 
autophagosome 
formation 
 Reduced cell 
proliferation 
 
 Inhibition of Wnt/ β-catenin 
signaling via β-catenin 
degradation  
 Inhibition of transcription of 
the Wnt target genes cyclin D1, 
c-Myc, and Axin2  
42
 
Colorectal 
Carcinoma 
HEK293 5μM 
Genistein 
 ↓ Phosphorylated 
GSK-3β 
 ↓ Nuclear β-
catenin 
 Decreased β-
catenin/Tcf 
complex 
formation 
 Decreased 
binding of β-
catenin/Tcf 
complex to DNA 
 ↓ Axin2  
 ↓ C-myc  
 ↓ Cyclin D1 
 Inhibition of Wnt/ β-catenin 
signaling via decrease in β-
catenin\Tcf complex formation 
and DNA binding  
 Inhibition of transcription of 
the Wnt target genes cyclin D1, 
c-Myc, and Axin2 
43
 
Human 
Embryonic 
Kidney 
HEK293 5μM 
Kaempferol 
 Decreased β-
catenin/Tcf 
complex 
formation 
 Inhibition of Wnt/ β-catenin 
signaling via decrease in β-
catenin\Tcf complex formation 
and DNA binding 
43
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Human 
Embryonic 
Kidney 
 Decreased 
binding of β-
catenin/Tcf 
complex to DNA 
 ↓ Axin2 
 ↓ C-myc  
 ↓ Cyclin D1 
 Inhibition of transcription of 
the Wnt target genes cyclin D1, 
c-Myc, and Axin2 
N/A Apigenin, 
Luteolin, 
Kaempferol 
 Inhibited GSK-
3β activity by 
binding its 
docking cavity 
 IC50 Apigenin: 
1.91±0.06μM 
 IC50 Luteolin: 
1.51±0.05μM 
 IC50 Kaempferol: 
3.47±0.11μM 
 GSK-3β phosphorylates 
numerous Wnt pathway 
molecules, including β-catenin, 
LRP5, and LRP6 
 
49
 
The symbol “↑” indicates an increase in whole cell protein (or the indicated activity), or 
upregulation, whereas the symbol “↓” indicates a decrease in whole cell protein (or the activity), 
or downregulation. 
 Flavonoids inhibit the Wnt signaling pathway in numerous ways. Primarily, flavonoids 
act to alter the metabolism of β-catenin. This can be achieved through the increased degradation 
of whole cell β-catenin, by preventing the entry of cytosolic β-catenin into the nucleus, a 
decrease in the binding of β-catenin to the TCF transcription factor, and the decreased binding of 
this complex to DNA.
42, 43, 48
 This in turn results in the reduced transcription of the Wnt pathway 
target genes cyclin D1, c-Myc, and Axin2.
42, 43, 48
 Flavonoids may also directly bind a regulator 
of the Wnt pathway, GSK3β, and inhibit its activity.49 In these ways flavonoids may be able to 
diminish the increased proliferative signaling of the Wnt pathway frequently seen in colorectal 
cancers.
57-59
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1.3.10 Epigenetic Effects of Flavonoids 
 It is possible that flavonoids affect such a broad range of intercellular signaling pathways 
because they also act as epigenetic modulators. Flavonoids can alter the enzyme activity as well 
as the abundance of proteins associated with DNA methylation or histone acetylation.
60
 In PC-3 
and 22Rv1 human prostate cancer cells, apigenin decreased both the enzyme activity and the 
protein expression of histone deacetylase proteins (HDAC); consequently this increased the 
acetylation of histones H3 and H4.
61
 Kaempferol in particular inhibits the enzymatic activity of 
all 11 known human HDAC proteins, which in turn increases the acetylation of histone H3 in 
HepG2 and Hep3B human hepatoma cells as well as in HCT-116 human colon carcinoma cells.
62
 
Genistein was found to decrease the enzyme activity and protein levels of DNA 
methyltransferases (DNMT) and HDACs in the HeLa human cervical cancer cell line.
63
 
Additionally, genistein decreased the global DNA methylation levels, DNMT activity, and levels 
of DNMT1 mRNA and protein in MCF-7 and MDA-MB-231 human breast cancer cells.
64
  
It is evident that, although they function similarly, the flavonoids can exert different 
epigenetic effects which may be further modified depending on the specific properties of the cell 
line being observed. Apigenin and luteolin were both found to reduce the enzyme activity of 
DNMTs extracted from the esophageal cancer cell line KYSE 510.
65
 However, luteolin was the 
more effective substance, having inhibited over 50% of DNMT activity at a concentration of 
50μM.65 In another study, apigenin decreased the protein expression of DNMT1, DNMT3a, and 
DNMT3b as well as HDAC 1-8 in mouse skin epidermal JB6 P+ cells.
66
 In HCT116 cells, 
luteolin had a similar function: it also decreased the protein expression of DNMT1, DNMT3a, 
and DNMT3b but only decreased the expression of HDAC proteins 1, 2, 3, 6, and 7.
67
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Most importantly, flavonoids have been observed to epigenetically regulate the 
transcription of genes associated with cancer. In MDA-MB-231 breast cancer cells, apigenin 
induced an increase in p21
WAF1/CIP1
 transcription by significantly inhibiting HDAC activity and 
inducing histone H3 acetylation.
38
 Treatment with genistein was found to increase the DNA 
methylation of Sfrp2, Sfrp5 and Wnt5a, thereby suppressing the expression of their gene 
products.
68
 This was achieved in conjunction with a reduction in histone H3 acetylation at the 
promoter regions of these genes; this reduced the binding ability of RNA polymerase II.
68
 
Kaempferol was found to decrease DACT2 methylation by binding DNMT1, and the resultant 
increase in DACT2 protein inhibited the expression of β-catenin which decreased the 
proliferation and migration of HCT116, HT-29, and YB5 colorectal cancer cell lines.
50
  
Dietary exposure to flavonoids during fetal development may also epigenetically 
“program” the individual as an adult. Agouti mice exposed to genistein only as prenates had 
significantly increased erythropoiesis and granulopoiesis as adults, and also experienced a 
hypermethylation of specific genes.
69
 As a result 20% of 21,742 gene products in the bone 
marrow were found to be differentially expressed.
69
 
1.4 Targets of Interest    
Described below are three cell surface proteins whose presence and activity within HT-29 
colorectal cancer cells may be altered following flavonoid exposure: CD26, CD38, and CD73. 
The expression of these proteins is found in colorectal cancers and changes upon the 
development of metastasis, which suggests that they may either impede or advance this 
process.
70-73
 CD26 and CD38 are both highly expressed within the immune system and may 
exert similar functions within colorectal cancer cells.
74, 75
 CD26 and CD73 have opposing 
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functions in the metabolism of the immunosuppressant adenosine; the former helps degrade it 
whereas the latter allows for its production.
73, 76
 Of these, CD26 is the principal target of interest.  
1.4.1 CD26 
CD26 (Figure 1.5) is an outward-facing 110kDa transmembrane enzyme that cleaves N-
terminal dipeptides in which proline or alanine are in the penultimate position.
77
 It is found on T-
cells, on the epithelial cells of the kidney, gastrointestinal tract, and bile duct, and its soluble 
form can be found in the plasma.
74
 Its substrates include a number of chemokines implicated in 
cell regulation, most notably the chemotactic compounds RANTES and CXCL12.
76
 By binding 
adenosine deaminase (ADA), CD26 is indirectly involved in the breakdown of adenosine, a 
molecule which stimulates colorectal cancer cell growth, increases the migratory response of 
colon cancer cells to CXCL12 by upregulating its receptor CXCR4, and acts as an 
immunosuppressant which inhibits the cytotoxic activities of NK and T cells present within the 
tumor microenvironment.
78-80
 Lastly, CD26 degrades the extracellular matrix (ECM) proteins 
fibronectin and collagen and thereby potentiates cell adhesion, migration, and invasion.
77
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Figure 1.5. Transmembrane CD26 has numerous functions.  
Its extracellular domain binds adenosine deaminase, degrades CXCL12, and binds extracellular 
matrix proteins including collagen and fibronectin. Its intracellular domain interacts with 
cytosolic proteins.
81
   
 
1.4.1.1 Cytoplasmic Processing of CD26  
Certain amino acid residues are important for the folding and transport of CD26. The 
location of specific prolines in the transmembrane domain of the CD26 peptide confer the 
appropriate conformation and hydrophobicity to allow the protein to move into the endoplasmic 
reticulum membrane.
82
 Mutating these residues causes the ejection of CD26 peptide from the 
membrane and its subsequent degradation in the cytosol.
82
 CD26 peptide conformation is also 
important for its leaving the endoplasmic reticulum; substituting Asp599 for Ala599 generated a 
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conformational change in the protein which increased its retention in the endoplasmic reticulum 
and subsequent degradation.
83
  
CD26 is then processed in the Golgi apparatus before it reaches its destination on the 
plasma membrane of the cell. In Caco-2 colon cancer cells, it was found that CD26 was 
glycosylated and formed homodimers in the Golgi apparatus.
84
 While glycosylation was not a 
prerequisite to the formation of homodimers in these cells, it was found that, in Caco-2 cells, 
CD26 needed to be inside the Golgi for it to dimerize.
84
 Results are contradictory, however, 
depending on the cell type being investigated. One study used Chinese hamster ovary cells 
transfected with rat CD26 protein: the mutation of the Asn319 residue, an N-glycosylation site 
on the extracellular part of CD26, to Gln319 prevented the dimerization of CD26.
85
 This in turn 
eliminated the cell surface expression and enzymatic activity of CD26.
85
 It was retained in the 
cytoplasm and its degradation was faster than that of other mutants or the wild-type protein.
85
 
The mutation of other N-glycosylation sites affected the protein in a similar fashion but to a 
diminished degree, suggesting that specific N-glycosylation sites are critical to proper CD26 
trafficking.
85
 
The glycosylation of CD26 also determines the location to which the protein will be 
distributed within the cell. In Caco-2 cells, it was found that inhibiting O-linked glycosylation 
induced a shift from CD26 appearing predominantly at the apical surface to being almost 40% 
basolateral.
86
 Inhibiting N-linked glycosylation, however, resulted in CD26 being equally 
distributed between the apical and basolateral membranes of Caco-2 cells.
86
 In HT-29 cells, N-
glycosylation was more important for the apical sorting of CD26 although both N-and O-
glycosylation were found to be necessary for apical sorting to be effective.
86
 Sialylation, a type 
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of glycosylation, has also been found to control apical targeting: its inhibition in MDCK and 
Caco-2 cells causes CD26 to be primarily secreted to the basolateral membranes.
87
   
The structure of CD26 itself may also carry targeting information that determines the 
location to which the protein is to be sent. In canine kidney MDCK cells transfected with rat 
liver CD26, it was found that the extracellular domain of CD26 contains information that allows 
the protein to be sorted to the apical side whereas the transmembrane and cytoplasmic domains 
contain basolateral targeting sites.
88
 
1.4.1.2 Transporting CD26 to the Plasma Membrane 
From the Golgi apparatus, CD26 is transported to the plasma membrane although the 
exact process by which this is done has yet to be elucidated. In Caco-2 cells, the adenylyl cyclase 
activator forskolin reduced 50% of CD26 at the apical surface without changing the total amount 
of CD26.
89
 The CD26 was found to accumulate in vesicles containing lamp-1, a lysosomal 
membrane protein, but not in the Golgi apparatus or Golgi-associated structures.
89
 CD26 was 
also located in these structures in non-treated cells, indicating that they represent a post-
transcriptional stage of intercellular transport.
89
 Further studies using this cell line showed that 
forskolin treatment reduced the expression of CD26 and two other proteins decreased throughout 
the entire cell surface, suggesting that a shared path of transport was affected.
90
 Endocytosis was 
found to be unaffected by this treatment demonstrating that the shuttling of CD26 to the cell 
surface was all that was affected.
90
 
Intercellular signaling may also affect the distribution of CD26. HepG2 hepatocytes were 
found to require E-cadherin/ β-catenin-associated adherens junctions in order to shift basolateral 
CD26 to the apical side of the cells.
91
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In the plasma membrane, CD26 binds to cholesterol-rich lipid microdomains, also known 
as lipid rafts.
86
 Glycosylation seems to be necessary here as well; inhibiting N- and O-linked 
glycosylation almost entirely inhibited this interaction in both HT-29 and Caco-2 cells.
86
 
Furthermore, inhibiting N- and O-linked glycosylation inhibited to a greater degree the 
association of CD26 with lipid microdomains in HT-29 than in Caco-2 cells.
86
  
The binding of CD26 to lipid rafts seems to have a great effect on its downstream 
activities and capabilities. In human Jurkat T-cells, the localization of CD26 to lipid rafts was 
determined to be necessary for downstream signaling events to occur.
92
 In the murine bone 
marrow cell line S17, it was found that purified lipid rafts constituted almost 75% of all CD26 
enzymatic activity.
93
 Indeed, it was found that the Km of CD26 was an order of magnitude 
smaller in the cell membranes than in the soluble forms of CD26 in FF18 and GR murine liver 
cells, SF murine skin cells, and FDC-P1 myeloid precursor cells.
93
  
It can be postulated that CD26 interacts with other lipid raft-bound proteins upon 
stimulation. Indeed, in T-cell lipid rafts, CD26 binds to Caveolin-1, which in turn recruits a 
complex of other proteins that together induce cell proliferation and NF-kB activation.
94
 CD26 
has also been found to translocate to the cell nucleus via caveolin-dependent endocytosis.
95
 
There, CD26 can interact with genes, and this has been seen to lead to the repression of POLR2A 
which caused a reduction in cell proliferation.
95
 These pathways may also exist in some colon 
cancers: Caveolin-1 mRNA was found in HT-29, HCT-116, and Caco-2 cells but Caveolin-1 
protein was only found in HT-29 and HCT-116 cell lines.
96
 The presence of Caveolin-1 was 
found to be proportional to the growth rate of the cells.
96
 The expression of Caveolin-1 in HT-29 
and DLD-1 colon carcinoma cells reduced the probability of tumor formation in vivo.
97
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Furthermore, Caveolin-1 protein levels were found to be reduced in human colon tumor 
epithelium as compared to normal colon epithelium for 10/15 patients tested.
97
  
1.4.1.3 CD26 and Cancer 
The relationship between CD26 activity and cancer growth varies depending on the type 
of cell being investigated. Compared to the normal cells of origin, CD26 expression is decreased 
in melanoma and hepatocellular carcinoma, variable in lung adenocarcinoma and ovarian 
carcinoma, and upregulated in prostate and thyroid cancers.
76
 The expression of CD26 is also 
associated with more aggressive T-cell lymphomas.
76
 With respect to colon cancer, one study 
found that CD26 mRNA and protein activity were increased within the colorectal cancer tissue 
of CRC patients compared to healthy subjects.
98
 
 The specific roles of both transmembrane and soluble CD26 in colorectal carcinomas are 
disputed; the molecular functions of CD26 suggest anticancer properties on the cellular level but 
its tissue distribution hints that it may help rather than hinder metastasis. It has been observed 
that CRC patients whose tumor tissues expressed high quantities of the CD26 protein had a 
significantly worse rate of survival than those whose tumors had a low expression of CD26.
99
 
The same study also found CD26 expression to be positively associated with late TNM stage and 
poorer differentiation, indicating its relevance to the metastatic state.
99
 With regards to cancer 
metastasis, it was found that the presence of CD26+ cells predicted distant metastasis on follow 
up in CRC patients.
100
 Likewise, CD26+ cells but not CD26- cells led to the development of 
distant metastases in a mouse model.
100
 Lastly, tumor cell migration, invasion, and adhesion to 
ECM of CD26+ cells were higher than CD26- cells.
100
  
 In contrast to tissue CD26, there does not seem to be a correlation between plasma CD26 
levels and tumor metastasis or patient survival. For instance, one study found that the amount of 
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plasma CD26 was increased in CRC patients compared to healthy subjects and that it was further 
increased in patients whose tumors had metastasized.
101
 Conversely, another study found that 
serum CD26 concentrations were significantly lower in CRC patients than in healthy plasma 
donors.
102
 Some studies show that plasma CD26 levels may indicate the occurrence of a 
metastatic event. Unstable plasma CD26 levels were found in postoperative CRC patients prior 
to local tumor recurrence; these increased and then decreased.
103
 Patients with metastatic disease 
had elevated plasma CD26 levels compared to patients whose tumors had gone into remission.
103
 
However, the levels of CD26 protein in the plasma may not correlate with the CD26 enzymatic 
activity. It was found that CRC patients had lower plasma CD26 activity than did healthy 
subjects.
98
 
It was found that the expression of CD26 protein and its enzyme activity were both 
correlated with the presence of a differentiated phenotype in HT-29 and Caco-2 cells.
104
 In Caco-
2 cells, this was found to be the period when the cells were no longer growing, but instead 
confluent.
104
 In HT-29 cells, differentiation was found to occur when they were grown in a 
glucose-deprived, inosine-supplemented medium.
104
   
In HCT116 and HCT-15 colon cancer cell lines, more CD26 mRNA and protein was 
produced as these cell lines became more confluent.
105
 The presence of c-Myc was found to 
repress CD26 expression whereas the presence of Cdx2 was found to increase it.
105
 Furthermore, 
serum depletion increased CD26 expression.
105
  
1.4.2 CD38 
The CD38 protein functions as both an enzyme and a receptor.
75
 Initially discovered to be 
a lymphocyte antigen, it is highly expressed within the immune system and is also expressed 
within the prostatic epithelium, pancreatic islet cells, kidney tubule cells, Purkinje cells, and 
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astrocytes.
75
 CD38 is believed to function when situated in the plasma membrane as well as 
when it is found in the intracellular and extracellular environments.
75
 As an enzyme, CD38 can 
either mobilize intracellular Ca
2+
 by converting NAD+ into cADPR  or induce an influx of 
extracellular Ca
2+
 by potentiating the activity of the transient receptor potential cation channel 
M2 (TRPM2).
106
 With respect to colorectal carcinomas, it has only been observed that CD38 
expression is heterogeneous and that it declines in the later stages of the tumor.
107
 
1.4.3 CD73  
 CD73 is an enzyme involved in the metabolism of extracellular adenosine- it converts 
adenosine monophosphate (AMP) into adenosine.
73
 CD73 is overexpressed in many cancer cell 
lines, including cancers of the colon, breast, ovaries, stomach, and gallbladder.
108
 It is said that 
the upregulation of CD73 within tumors is an adaptation that helps cancer cells evade immune 
system surveillance.
109
 The production of adenosine by CD73 helps promote tumor growth by 
providing an immunosuppressive extracellular environment.
110
 CD73 levels are also upregulated 
during hypoxia and it has been hypothesized that CD73 decreases the permeability of the 
intestinal epithelium.
111
 Mice lacking CD73 are more susceptible to colitis and have altered 
gastrointestinal inflammatory responses.
112
 With respect to colon cancer, CD73 is of particular 
interest because it has been found in significantly higher quantities within metastatic colon 
tumors than in primary colon tumors or in normal colonic mucosa.
109
  
1.5 Culture Cell Density 
The population density of cultured cancer cells is an important characteristic which can 
significantly affect experimental outcomes.
113
 Shifts in culture cell density can generate changes 
in protein and miRNA expression, cell invasiveness, and molecular uptake.     
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1.5.1 Cell Density and Protein Expression 
As cancer cells approach confluence, they encounter more intercellular interactions and 
junctions and correspondingly less space into which to grow, which has an effect on their 
transcriptome. In MDA-MB-231 breast cancer cells, it was found that over 2,000 genes had at 
least a 2-fold difference in expression between 50% and 90% confluent cultures.
114
 An increase 
in cell density has been shown to affect cellular lipid composition and endocytosis as well as 
specific signalling pathways.
113
 These include a decrease in MTOR signalling, a decreased 
expression of the mature lysosomal protein cathepsin D, and a decrease in the levels of the 
autophagic proteins p62 and pS6 in a number of cancer cell lines.
113
 Of note is that the quantity 
of abundant proteins like GAPDH and β-actin remains unchanged as cell density increases.113 
This demonstrates that only a subset of cell proteins are affected by cell density, and in particular 
suggests that these two specific proteins are appropriate choices for loading controls in PCR and 
immunoblotting experiments.  
1.5.2 Cell Density and miRNA Expression 
The Hippo pathway is said to mediate cell-density dependent signals that determine the 
metastatic ability of cancer cells.
115
 The proteins YAP and TAZ act as effectors which bind the 
TEAD transcription factor target genes, translocate into the nucleus and alter gene transcription 
upon activation by upstream extracellular signalling and cell-cell contact.
115
 When cells are 
subconfluent, nuclear YAP binds p72 which in turn suppresses microRNA expression.
116
 Indeed, 
many human cancers have been found to have decreased miRNA in comparison to their normal 
tissue of origin.
116
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1.5.3 Cell Density and Invasiveness 
Cell growth density has been shown to be an important factor in the invasiveness of cells. 
Human breast cancer MDA-MB-231 cells at low density were shown to easily invade an 
endothelial cell monolayer.
117
 In contrast, the same cells cultured to confluence had a 
significantly less invasive phenotype.
117
 This effect was found to not be caused by altered cell 
proliferation or apoptosis rates which could have been induced by the difference in culture 
confluence.
117
 As well, this effect was reversed once the cells were reverted to the low-
confluence culture state.
117
 The invasiveness of Colo357 pancreatic cancer cells was not affected 
by cell density, however.
117
 In MDA-MB-231 cells, the same effect was seen in vivo: cells grown 
at low density were more readily able to invade to vasculature of zebrafish yolk sacs and also 
extravasate from the blood vessels of the adult fish into surrounding tissues.
117
 
1.5.4 Cell Density and Molecular Uptake 
Cell growth density may also be relevant to the uptake of molecules into the cells. In both 
HT-29 and Caco-2 cell lines, it has been shown that excitatory amino acid transporters (EAATs) 
localize from the nuclei to the plasma membrane when the cells became confluent.
118
 This in turn 
significantly increased their glutamate uptake and decreased their glutamate secretion, 
respectively.
118
 Curiously, confluent HT-29 cells also saw a reduced passive diffusion of 
anthracycline drugs across their membranes in comparison to subconfluent cells.
119
 This suggests 
that changes occur within the plasma membrane itself as cells approach the confluent state.  
Confluence dependent resistance is an observed phenomenon in cell lines including colon 
cancers. Confluent HT-29 cells were found to be more resistant to and have a lower intracellular 
accumulation of doxorubicin, vincristine, etoposide, cisplatin, melphalan, and 5-fluorouracil than 
subconfluent cells.
120
 The levels of p27 have also been found to be increased in confluent HT-29 
27 
 
cells.
121
 Furthermore, the transfection of p27 into subconfluent HT-29 cells increases their 
resistance to cisplatin, doxorubicin, etoposide, and 5-fluorouracil.
121
  
1.6 Rationale of the Project  
 The cell-surface proteins CD26, CD38, and CD73 are present in colon cancers although 
their specific contributions to the development of these cancers are as yet incompletely known. It 
may though be possible to modulate their presence and function within colon cancer cells using 
substances which alter their production, metabolism, or enzymatic activity. This may have an 
impact on development of the cancer. 
One such substance is the dietary flavonoid apigenin, which has been found to increase 
the levels of CD26 protein on the surface of HT-29 colorectal cancer cells.
15
 However, the 
specific mechanism by which this phenomenon occurs has not been identified. The flavonoids 
genistein, kaempferol, and luteolin are similar in structure to apigenin and are similarly bioactive 
in many models of other cancer cell functions. It is therefore likely that they exert the same 
effects on CD26 as does apigenin. It is possible that apigenin, genistein, kaempferol, and luteolin 
also affect the levels of CD38 and CD73 in HT-29 cells. 
Cancer cell behaviour in vitro and in vivo is modulated by the extracellular environment. 
Cancer cell population density in particular is a crucial factor which can give rise to numerous 
behavioural adaptations. CD26 expression has been shown to be dependent upon cell culture 
density. 
Therefore the purpose of this project was to examine the effects of apigenin, genistein, 
kaempferol, and luteolin on the levels of CD26, CD38, and CD73 within both confluent and 
subconfluent cultures of HT-29 colorectal cancer cells. 
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1.7 Hypothesis 
 Apigenin and the related flavonoids genistein and luteolin will increase the levels of 
CD26, CD38 and CD73 in HT-29 colorectal carcinoma cells, and this will be dependent on cell 
population density (culture confluency).  
1.8 Specific Objectives 
The objectives of this project were to:  
1. Compare changes in CD26, CD38, and CD73 mRNA in HT-29 cells in response to 
apigenin treatment at different confluence levels, and to decide which of these three 
components to investigate further.   
2. Quantify changes in HT-29 cell viability in response to treatment with increasing 
concentrations of apigenin, genistein, kaempferol, or luteolin, to exclude changes that 
may be dependent on toxicity.  
… and then having identified CD26 as the preferred candidate and accounted for the possibility 
of toxicity due to high doses of these flavonoids: 
3. Quantify changes in the mRNA and protein expression of CD26 in HT-29 cells 
treated with apigenin, genistein, kaempferol, or luteolin in both confluent and 
subconfluent states. 
4. Observe changes in the abundance and localization of CD26 protein in HT-29 cells 
treated with apigenin, genistein, kaempferol, or luteolin. 
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2 Methods 
2.1 Cell Culture  
 HT-29 colorectal cancer cells were cultured in T-75 flasks (Thermo Scientific) kept at 
37ºC and 10% CO2. HyClone Dulbecco’s Modified Eagle Medium (GE Life Sciences) 
containing 4mM L-glutamine, 4500mg/L glucose, 1mM sodium pyruvate (ThermoFisher 
Scientific), and 10% newborn calf serum v/v (Fisher Scientific) was used. Cells nearing 
confluence were passaged using 1mL 0.25% Trypsin-EDTA (Fisher Scientific) for 2min at room 
temperature to release them from the flasks. 
Apigenin (Sigma-Aldrich), genistein (Sigma-Aldrich), kaempferol (Sigma-Aldrich), and 
luteolin (Sigma-Aldrich) dissolved in DMSO were used to treat the cells. Flavonoid aliquots 
dissolved in DMSO were stored at -80ºC until the time of treatment, in which culture media was 
replaced with serum-free medium containing the required dilution of flavonoid. The 
concentration of DMSO was no greater than 0.4% v/v for every treatment.  
2.2 Cell Counting 
 A Neubauer chamber hemacytometer (Fisher Scientific; 0267110) was used to count cells 
prior to their being seeded in 6-well plates (Thermo Scientific; 140675). Cells suspended in 
media were taken into a glass pipette using capillary action and introduced to the hemacytometer 
to fill it. A Nikon Eclipse TE200 inverted microscope with a 20x objective lens was used to view 
the cells. The central big square of the Neubauer chamber was used to count the number of cells. 
Cells on the upper and left-hand boundaries of this square were included into the count whereas 
cells on the lower and right-hand boundaries were not. Six measurements were made with the 
hemacytometer being cleaned with water and dried off between each count. The six 
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measurements were averaged into one value, representative of the number of cells per 0.1µL of 
cell suspension.  
The number of cells seeded per unit area was kept constant at 62,500/cm
2
 throughout all 
experiments conducted. Therefore the number of cells seeded into one well of a 6-well plate, 8-
well chamber slide, or 96-well plate was 600,000, 61,250, and 18,263, respectively.   
2.3 MTT Assay 
 A 96-well plate was loaded with a 200µL suspension of cells in media. After 48 hours, 
the media was replaced with cell media treated with the reagents of interest. Each treatment was 
used 6 times. After 48 hours of treatment, 20µL of 5mg/mL MTT (Sigma-Aldrich) in phosphate-
buffered saline (PBS; see Appendix) was added to each well. The plates were manually shaken 
and then incubated at 37ºC for 1h. The plates were then inverted such that the media and MTT 
solution was drained off and 100µL DMSO was added to each well. The plates were then shaken 
using a Hoefer Red Rotor PR70 platform shaker for 30min at room temperature. The absorbance 
of the wells at 492nm was measured on a M5 Spectramax spectrophotometer (Molecular 
Devices). 
2.4 RNA Extraction 
Upon reaching the desired confluence level, the 6-well plates were placed on ice. The 
media was aspirated and the flasks rinsed twice with 2mL ice-cold phosphate-buffered saline 
with calcium and magnesium (PBS Ca
2+
/ Mg
2+
; see Appendix). The PBS Ca
2+
/ Mg
2+
 was 
discarded and 1.25mL TRI Reagent (Invitrogen) was added to each well. The cells were lysed by 
pipetting this solution several times within the flasks. The flasks were then left for 5min at room 
temperature before the contents were transferred to 1.5mL microcentrifuge tubes and 0.25mL 
chloroform (Sigma-Aldrich) was added to each tube. The tubes were vortexed for 3-5s to mix the 
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solutions together and then incubated for 5min at room temperature. The tubes were then 
centrifuged at 12,000 x g for 10min at 4ºC using an Eppendorf 5424R microcentrifuge. The 
aqueous phases containing the RNA were then transferred to a new set of 15mL tubes. 3M 
potassium acetate (Sigma-Aldrich) consisting of 10% of the volume of the aqueous RNA was 
added to each tube as well as 625µL of isopropanol. The tubes were inverted several times to 
mix them before being incubated for 10min at room temperature and subsequently centrifuged at 
12,000 x g for 15min at 4ºC. The supernatant was removed after which 1.25mL of 75% ethanol 
was added to the pellet and mixed in by inverting the tubes. The tubes were then centrifuged at 
12,000 x g for 5min at 4ºC. The supernatant was removed and discarded and the pellet dissolved 
in 50μL autoclaved Milli-Q® water. The RNA concentration and purity values were then 
measured using a nanodrop (Thermo Scientific 200c).  
2.5 Reverse Transcription 
Master mix 1 was composed of volumes of 0.5μg/μL oligo dT (Jena Bioscience), 10mM 
dNTP (Thermo Scientific), and with diethyl pyrocarbonate (DEPC)-treated water mixed in a 
2:5:3 ratio. Each reaction tube was filled with 5μL master mix 1 and 2.5μg of RNA before being 
diluted with DEPC-treated water until the total volume reached 25μL. The tubes were then 
placed into the thermocycler (Fisher® Techne Genius #FGENO2TP) and heated to 65ºC for 
5min. Afterwards, they were chilled on ice for 15s before 20μL of master mix 2 was added to 
each tube. Master mix 2 was comprised of a 4:2:1:1 ratio, by volume, of 5x first strand (FS) 
buffer (Invitrogen), dithiothreitol (DTT) (Invitrogen), RNAse Out™ ribonuclease inhibitor 
(Invitrogen), and 200 U/μL Moloney murine leukemia virus reverse transcriptase (M-MLV RT) 
(Invitrogen). The tubes were then put back into the thermocycler, heated to 37ºC for 50min, and 
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then heated to 70ºC for 15min, after which the product was stored at -80ºC. Negative controls 
were made using autoclaved Milli-Q
®
 water instead of M-MLV RT.  
2.6 Primer Design 
 DNA primer sets for qPCR were purchased from Invitrogen Canada. The sequences were 
designed as follows: 
1. CD26 
a. Forward: 5’-CGCTCCTTCTCTGAACGCTC-3’ 
b. Reverse: 5’-AGCATCATCTGTGCCTTTGTTC-3’ 
2. CD38 
a. Forward: 5’-ATTCCAGAGACTTATGCCAGA-3’ 
b. Reverse: 5’-GCTAAAACAACCACAGCGACT-3’ 
3. CD73 
a. Forward: 5’-GATGAACGCAACAATGGCAC-3’ 
b. Reverse: 5’-GCACGCTATGCTCAAAGGC-3’ 
4. GAPDH 
a. Forward: 5’-CGACCACTTTGTCAAGCTCA-3’ 
b. Reverse: 5’-AGGGGTCTACATGGCAACTG-3’ 
The primer sets were designed using the National Center for Biotechnology Information 
(NCBI) PrimerBLAST program after referencing the sequences for human CD26 and GAPDH 
mRNA using the NCBI Nucleotide database. Primers were selected such that they met as many 
of the following criteria as possible: the primer pair was separated by at least one intron on the 
corresponding genomic DNA, each primer spanned 18-25 base pairs long, had a product size 
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between 80-250 base pairs, a melting temperature (Tm) between 58-61ºC, not more than a 2ºC 
difference in Tm between the pair, and not more than 3 G or C bases out of the last 5 bases on the 
3’ end of the primer.  
2.7 End-Point PCR 
 Each end point PCR reaction contained 2.5μg cDNA, 12.5μL GoTaq Green, 0.5μL 
forward primer, 0.5μL reverse primer, and 9.5μL MilliQ H2O. A Techne Genius FGEN02TP 
thermal cycler was used to heat the reactions to 36 cycles of the following: 94ºC for 45s 
(denaturing), 60ºC for 45s (annealing), and 72ºC for 60s (extension), before a final extension 
period of 72ºC for 10 min. Next, 5μL of each sample was loaded into a 1% agarose gel. 
Electrophoresis ran at 95V for 30min after which an Alpha Imager HP machine was used to 
image the gels. Intermediary troubleshooting steps, including primer and reagent verification, 
can be seen in Figures 2.1 and 2.2.    
 
Figure 2.1. Testing different primer sets on a collection of HT-29 RNA using gel PCR.  
The lanes labelled “1” and “2” denote two different sets of primers used for CD26 and CD73, 
respectively. CD26 primer set 1 and CD73 primer set 1 resulted in better band resolution than 
CD26 primer set 2 and CD73 primer set 2, respectively.    
CD26   CD73  
1    2    1    2   
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Figure 2.2. Testing different sources of water to be used in the reverse transcription 
reaction.  
The water used to reverse transcribe the cDNA in the lanes labelled “1” was DEPC-treated H2O 
and gave clear banding at the appropriate molecular weights according to the ladder. This 
indicates that the reverse transcription was successfully completed. The water used to reverse 
transcribe the cDNA in the lanes labelled “2” was MilliQ. It was likely contaminated with 
RNAses and as such the reverse transcription was not successfully completed. This is evident 
from the absence of banding seen in the lanes labelled “2”.  
 
2.8 Quantitative PCR 
  First, cDNA was diluted to 5ng/µL in DEPC-treated water. Next, the qPCR reactions 
were made such that each 20μL reaction contained 5ng cDNA, 10μL SSO Advanced SYBR 
Green qPCR Mix (Bio-Rad Laboratories), 200nm forward primer, and 200nm reverse primer. A 
StepOnePlusTM Real-Time PCR System was used to heat the qPCR reactions to 95ºC for 30s to 
activate the polymerase and then 40 cycles of 15s at 95ºC for denaturation and 60s at 60ºC for 
annealing and extension. The ΔΔCT relative quantification method was used to determine 
changes in the expression of the CD26 gene. LinRegPCR
®
 was used for data analysis and to 
produce a quantification cycle (CT) value for each sample, the number of cycles needed to reach 
the fluorescence threshold. This was then used to determine the N0 value which is relative to the 
GAPDH  CD26   
1    2     1   2    
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starting concentration of CD26 cDNA. The N0 values of CD26 in each sample were normalized 
to N0 values of GAPDH. 
2.9 Protein Extraction  
 The media was aspirated from each well before the cells were washed with ice-cold PBS 
Ca
2+
/ Mg
2+
. Next, the PBS Ca
2+
/ Mg
2+
 was aspirated and 0.4mL ice-cold 
radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors (see Appendix) 
was added to each well. The cells were then incubated for 30min at 4ºC (on ice) and agitated 
using a Hoefer Scientific Red Rotor #PR70-115V. The lysates were pipetted, collected into 
1.5mL microcentrifuge tubes, and vortexed for 10s (Fischer Scientific; 02215370). An 
Eppendorf 5424R microcentrifuge was used to centrifuge the tubes at 14,000 x g for 20min at 
4ºC to pellet the membranes. The supernatant was collected and transferred to a fresh 
microcentrifuge tube before protein concentration was determined using the Bradford assay.  
2.10 Bradford Assay 
 Protein standards of 0, 50, 125, 250, 375, 500, 750, and 100µg/mL were made using 
bovine serum albumin (Alfa Aesar) in 20% RIPA buffer. A 96-well plate was loaded with 5µL 
of each standard in triplicate. Protein samples were diluted 5-fold in Milli-Q water and 5µL of 
each sample was loaded into the plate using a total of 6 replicates per sample. Next, 200µL of 
Bradford reagent (Bio-Rad Laboratories) were added to each well and mixed by pipetting. The 
absorbance of the wells at 595nm was measured on a M5 Spectramax spectrophotometer 
(Molecular Devices). The protein concentrations were calculated using the standard curve given 
by the absorbance values of the protein standards.  
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2.11 Western Blot  
 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used for 
protein detection. The protein samples, dissolved in RIPA buffer, were further dissolved into 2X 
Laemmli sample buffer (see Appendix) such that there were equal proportions of RIPA buffer 
and 2X Laemmli sample buffer. They were heated at 90ºC for 10min after which 30µL of each 
sample as well as 5-10µL of protein ladder (FroggaBio) was loaded into the wells. The 
electrophoresis was then completed using polyacrylamide gels (see Appendix) in running buffer 
(see Appendix) at 30mA for 3h (Bio-Rad ® PowerPac™ HC 250v/3.0A/300w western blot SDS-
PAGE). The proteins were then transferred from the gel onto an Immun-Blot® PVDF membrane 
(Bio-Rad Laboratories) for 16h at 10V (Bio-Rad Laboratories PowerPac™ HC 250v/3.0A/300w 
western blot SDS-PAGE) at 4ºC in transfer buffer (see Appendix). The membrane was then 
blocked by being incubated with 3% BSA in TBS-T (see Appendix) for 1h at room temperature. 
After the blocking solution was discarded, 10mL of rabbit IgG anti-human CD26 primary 
antibody (Abcam; ab129060) diluted 1:50,000 in TBS-T with 1% BSA was added to the 
membrane and incubated for 2h at room temperature. For use as a loading control, 10mL 
solution of HRP-conjugated mouse IgG anti-β-actin antibody (Abcam) diluted 1:1,000 in TBS-T 
with 1% BSA was added to the membrane and left to incubate for 2h at room temperature. The 
membrane was then washed 5 times for 5min each with 20mL TBS-T at room temperature. A 
10mL solution of horseradish peroxidase (HRP)-conjugated goat IgG anti-rabbit IgG secondary 
antibody (ThermoFisher Scientific; 31460) diluted between 1:1,000-1:5,000 in TBS-T with 1% 
BSA was added to the membrane and left to incubate for 1h at room temperature. The membrane 
was again washed 5 times for 5min each with 20mL TBS-T at room temperature. Then, 3mL 
chemiluminescent solution (see Appendix) was added to the membrane for 5min at room temp. 
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Afterwards, the Kodak Image Station 4000 MM Pro was used to image the proteins on the 
membrane. Intermediary troubleshooting steps, including antibody verification and protocol 
optimization, can be seen in Figures 2.3, 2.4, and 2.5.                   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Immunoblots comparing two CD26 antibodies.  
Protein collected from HT-29 cells treated with vehicle control (0μM), 6μM, 20μM, or 60μM 
apigenin was transferred onto PVDF membranes and immunoblotted with two different rabbit 
IgG anti-human CD26 primary antibodies. The antibody used in panel A (Abcam; ab28340) 
shows nonspecific binding whereas the antibody used in panel B (Abcam; ab129060) does not. 
The 100kDa protein marker has been noted on the image to indicate the expected location of 
CD26 banding according to its molecular weight. 
 
 
Figure 2.4. Comparing two different wet transfer protocols.  
Protein collected from HT-29 cells treated with vehicle control (0μM), 6μM, 20μM, or 60μM 
apigenin was transferred onto PVDF membranes using two different protocols. The proteins in 
panel A were transferred at 100V for 1h whereas the proteins in panel B were transferred at 10V 
for 16h. The membranes were immunoblotted with the same rabbit IgG anti-human CD26 
[Apigenin]: 0µM  6µM  20µM  60µM A  B  [Apigenin]: 0µM   6µM  20µM  60µM 
100kDa  100kDa  
A  B  [Apigenin]: 0µM 6µM 20µM 60µM [Apigenin]: 0µM 6µM 20µM 60µM 
100kDa  100kDa  
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primary antibody (Abcam; ab129060). The transferring protocol used in panel B displayed better 
protein resolution. The 100kDa protein marker has been noted on the image to indicate the 
expected location of CD26 banding according to its molecular weight. 
 
 
 
 
 
 
 
 
Figure 2.5. Confirming that the antibody selected for experimental work binds the CD26 
protein.  
Purified CD26 protein (Abcam) was transferred onto PVDF membranes. The membrane in panel 
A was immunoblotted with a rabbit IgG anti-human CD26 primary antibody (Abcam; 
ab129060), whereas the membrane in panel B was immunoblotted with the same antibody in 
combination with a CD26 peptide (Abcam). The antibody in panel A bound the purified CD26 
protein in the membrane. However, the antibody in panel B bound the CD26 peptide but not the 
CD26 protein in the membrane, confirming that this antibody specifically binds CD26. The 
100kDa protein marker has been noted on the image to indicate the expected location of CD26 
banding according to its molecular weight. 
2.12 Immunofluorescent Staining  
 Cells were grown in 8-chamber slides (SPL Life Sciences). The plates were placed on ice 
and the media was aspirated. Each well was washed with 200μL cold PBS Ca2+/ Mg2+. The wash 
was aspirated and the cells fixed with freshly prepared 1% paraformaldehyde (EMD Millipore; 
see Appendix) in PBS Ca
2+
/ Mg
2+
 for 10min at room temperature. The cells were then washed 
three times with PBS Ca
2+
/ Mg
2+
. The cells were blocked using 3% BSA (Alfa Aesar) v/v in 
200μL PBS Ca2+/ Mg2+ per well for 30min at room temperature. This was aspirated and 200μL 
rabbit IgG anti-human CD26 primary antibody (Abcam; ab28340) in PBS Ca
2+
/ Mg
2+
 with 
1mg/mL BSA was added to each well. The chamber slides were incubated in a humidified 
A  B  
100kDa  100kDa  
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chamber for 1.5h at room temperature. The primary antibody solution was aspirated and the 
wells washed three times with 200μL PBS Ca2+/ Mg2+ containing 1mg/mL BSA. Each wash was 
performed on a rotary platform mixer (Hoefer Red Rotor PR70) at low speed for 5min at room 
temperature. Next, 200μL goat IgG anti-rabbit IgG secondary antibody conjugated to green 
AlexaFluor 488 (Life Technologies) in PBS Ca
2+
/ Mg
2+
 with 1mg/mL BSA was added to each 
well. The chamber slides were again incubated in a humidified chamber for 1h at room 
temperature. The secondary antibody solution was aspirated and the wells washed three times 
with 200μL PBS Ca2+/ Mg2+ containing 1mg/mL BSA. Each wash was performed on a rotary 
platform mixer at low speed for 10min at room temperature. This was aspirated and the wells 
washed three times with 200μL cold PBS Ca2+/ Mg2+ per well. After aspirating this wash, cells 
were treated with either CellMask Deep Red (ThermoFisher Scientific) to stain the plasma 
membrane or Fluoroshield aqueous gel mountant containing 1 μg/mL 2-(4-amidinophenyl)-1H-
indole-6-carboxamidine (DAPI) (Sigma-Aldrich) before the coverslip was added. With the 
assistance of Dr. Marianna Foldvari and Dr. Roger Chen, fluorescence was visualized using a 
Zeiss LSM710 confocal laser scanning microscope (Carl Zeiss, Jena, Germany) using Ar-laser 
(488nm) and HeNe-laser (633nm) lines and either the Plan-Apochromat 20x/0.80 dry objective 
or the 63x/1.40 oil immersion objective. A ‘no treatment’ sample was used to confirm gain and 
pinhole settings to exclude noise and autofluorescence background for the subsequent treatment 
samples. Images were captured and processed using the Zen 2009 software. A Leica DM2000 
microscope with a 100x oil immersion objective was also used to visualize cells before capturing 
and processing images with the QCapture Pro 7 software.  
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2.13 Statistical Analysis 
 GraphPad Prism 5 software was used to analyze the data collected. One-way analysis of 
variance (ANOVA) followed by Dunnett’s multiple comparisons test were used to analyze the 
data obtained from the MTT experiments. Two-way ANOVA followed by Bonferroni’s multiple 
comparisons test were used to analyze the data obtained from the qPCR and western 
immunoblotting experiments. A value of p<0.05 was chosen as the threshold for statistical 
significance.  
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3 Results 
3.1 Evaluating Changes in the Levels of CD26, CD38, and CD73 mRNA in Response to 
Apigenin Treatment at Different Cell Confluence Levels 
The potential effects of the flavonoid apigenin on the mRNA expression for the enzymes 
CD26, CD38, and CD73 were investigated in HT-29 cells. To account for the possibility that cell 
confluence level might influence the transcription of these genes and their response to flavonoid, 
HT-29 cells were treated with apigenin for 24h such that the mRNA could be collected from 
cells when the population was at 65%, 90%, or 100% confluence. End-point PCR was used in 
conjunction with agarose gel electrophoresis as a method by which differences in gene 
transcription could be rapidly identified.  
The results are shown in Figure 3.1.  Based on indications from the gel band intensities, 
there was strong suggestion of an upregulation of CD26 mRNA levels in apigenin-treated cells 
harvested at 90% and 100% confluence but not in those harvested at 60% confluence (Figure 
3.1A). There might also be a slight upregulation of CD38 mRNA in apigenin-treated cells 
collected only at 100% confluence (Figure 3.1B), however this change if present was too minor 
to be likely to be biologically relevant and was therefore not investigated further. There was no 
sign of a change in CD73 mRNA due to apigenin treatment at any confluence level or time of 
mRNA collection (Figure 3.1C). It was therefore decided not to further investigate potential 
changes in CD38 or CD73 in response to flavonoids, of which apigenin is the main example. 
CD26 was chosen as the focus of subsequent experimental work.   
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Figure 3.1. The effects of apigenin treatment on the amounts of CD26, CD38, and CD73 
mRNA in HT-29 cells collected at different confluence levels.  
HT-29 cells were treated with vehicle control (0μM) or 60μM apigenin for 24h. Three groups of 
cells were treated such that mRNA was collected from cells at approximately 65%, 90%, or 
100% confluent densities, respectively. mRNA reverse transcribed to cDNA was used for these 
gel electrophoresis experiments. Then the amounts of (A) CD26, (B) CD38, and (C) CD73 
cDNA in each sample were visualized. The first lane in each image shows a DNA ladder, and the 
number of base pairs (b.p.) in each band has been marked with arrows. CD26 and CD73 
amplicon lengths were approximately 150 b.p. long, and as such the bands can be seen slightly 
below the 200 b.p. band on the DNA ladder. CD38 amplicon lengths were approximately 200 
b.p. long, and as such the bands can be seen adjacent to the 200 b.p. band on the DNA ladder. 
GAPDH loading control amplicon lengths were approximately 230 b.p. long, and as such the 
bands can be seen slightly above the 200 b.p. band on the DNA ladder. Images are representative 
of three experimental replicates.   
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3.2 Assessing Flavonoid Cytotoxicity Using a MTT Assay 
I now added three flavonoids structurally and functionally related to apigenin, namely 
genistein, kaempferol, and luteolin, to this study to investigate the potential effects of all four 
related flavonoids on the abundance, expression, and localization of CD26 as a single marker. 
The potential cytotoxicity of each flavonoid within HT-29 cells was investigated using 
MTT assays so as to determine the maximal flavonoid concentrations would not induce 
cytotoxicity. HT-29 cells were treated with each of these flavonoids for 24h. Based on data from 
the MTT assay, only luteolin treatments significantly changed cell viability (Figure 3.2). 
Apigenin, genistein and kaempferol were without any effect at concentrations up to 100μM 
(Figure 3.2 panels A-C). 
The effect of luteolin was unexpectedly biphasic (Figure 3.2D). Treatments of 3μM and 
10μM luteolin increased cell growth, by approximately 11% and 13%, respectively, whereas 
100μM luteolin decreased cell viability by approximately 20% (Figure 3.2). 
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Figure 3.2: Cell viability after flavonoid treatment as measured by an MTT assay.  
HT-29 cells were treated with (A) apigenin, (B) genistein, (C) kaempferol, or (D) luteolin for 
24h at the indicated concentrations. Cell viability was measured using an MTT assay in which 
each reaction was performed in six replicates. Percent maximal absorbance was calculated by 
dividing the absorbance of each experimental sample by the average absorbance of the control 
samples. The data are means ± SEM. Each graph represents three independent experiments. 
Statistical analysis was done using one-way ANOVA with Dunnett’s multiple comparisons test. 
3μM and 10μM luteolin significantly increased cell growth, whereas 100μM luteolin 
significantly decreased cell viability. * p < 0.05, *** p < 0.001   
 
 
 
 
A B 
C D 
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3.3 Measurements of the Transcription of CD26 mRNA in Response to Flavonoids 
 Possible changes in the transcription of CD26 mRNA were further explored and 
quantified using qPCR. Based upon the prior findings with end-point PCR (Figure 3.1A) I 
allowed for the possibility of dependence on cell population density in these experiments. 
HT-29 cells were grown to less than 60% (low) confluent density (no response expected, 
Figure 3.1A) or to 90-100% (high) confluence (response expected, Figure 3.1A) before being 
treated with vehicle control (0μM), 30μM or 60μM of apigenin, genistein, kaempferol or luteolin 
for 24h.  
The effects of each flavonoid on the mRNA of CD26 in HT-29 cells treated at these low 
or high confluence levels are shown in Figures 3.3, 3.4, 3.5, and 3.6. Despite significant 
differences in average values (e.g. 60μM apigenin at high confluence, +55%, 60μM luteolin at 
low confluence, +110%) there were no statistically significant changes with respect to the 
transcription of CD26 mRNA following treatment with either concentration of any of the four 
related flavonoids at either confluence level. It may be that statistical significance was difficult to 
attain due to the potential variation from environmental factors such as population density (see 
further comments in Discussion). 
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Figure 3.3 CD26 mRNA expression in HT-29 cells treated with apigenin at different 
confluence levels. 
HT-29 cells were treated at low or high confluence with apigenin for 24h at the indicated 
concentrations. mRNA reverse transcribed to cDNA was used in triplicate reactions for each 
independent experiment. CD26 mRNA data was first normalized to the levels of GAPDH mRNA 
found in each sample before the ∆∆Ct method was used to quantify the fold difference in CD26 
mRNA expression in each sample relative to the untreated control. Data is presented as mean ± 
SEM from three independent experiments. Statistical analysis was done using two-way ANOVA 
with Bonferroni’s post-test used to compare the replicate means. 
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Figure 3.4 CD26 mRNA expression in HT-29 cells treated with genistein at different 
confluence levels. 
HT-29 cells were treated at low or high confluence with genistein for 24h at the indicated 
concentrations. mRNA reverse transcribed to cDNA was used in triplicate reactions for each 
independent experiment. CD26 mRNA data was first normalized to the levels of GAPDH mRNA 
found in each sample before the ∆∆Ct method was used to quantify the fold difference in CD26 
mRNA expression in each sample relative to the untreated control. Data is presented as mean ± 
SEM from three independent experiments. Statistical analysis was done using two-way ANOVA 
with Bonferroni’s post-test used to compare the replicate means. 
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Figure 3.5 CD26 mRNA expression in HT-29 cells treated with kaempferol at different 
confluence levels. 
HT-29 cells were treated at low or high confluence with kaempferol for 24h at the indicated 
concentrations. mRNA reverse transcribed to cDNA was used in triplicate reactions for each 
independent experiment. CD26 mRNA data was first normalized to the levels of GAPDH mRNA 
found in each sample before the ∆∆Ct method was used to quantify the fold difference in CD26 
mRNA expression in each sample relative to the untreated control. Data is presented as mean ± 
SEM from three independent experiments. Statistical analysis was done using two-way ANOVA 
with Bonferroni’s post-test used to compare the replicate means. 
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Figure 3.6 CD26 mRNA expression in HT-29 cells treated with luteolin at different 
confluence levels. 
HT-29 cells were treated at low or high confluence with luteolin for 24h at the indicated 
concentrations. mRNA reverse transcribed to cDNA was used in triplicate reactions for each 
independent experiment. CD26 mRNA data was first normalized to the levels of GAPDH mRNA 
found in each sample before the ∆∆Ct method was used to quantify the fold difference in CD26 
mRNA expression in each sample relative to the untreated control. Data is presented as mean ± 
SEM from three independent experiments. Statistical analysis was done using two-way ANOVA 
with Bonferroni’s post-test used to compare the replicate means.  
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3.4 Measurement of CD26 Protein Levels Using Western Immunoblotting 
Whole cell levels of CD26 protein were quantified using western immunoblotting, 
followed by densitometry of the images and normalization to levels of β-actin. As before, HT-29 
cells were grown to grown to less than 60% (low) confluent density or to 90-100% (high) 
confluence before being treated with vehicle control (0μm), 30μM or 60μM of apigenin, 
genistein, kaempferol, or luteolin for 24h. This is consistent with the timecourse for initial 
changes in protein appearance in response to apigenin as measured in terms of immunoreactive 
CD26 at the surface of viable cells.
15
 It was chosen rather than a later timepoint of e.g. 48h to 
remain close to the desired confluence levels (cultures from the lower confluence level may have 
then been approaching the higher cell density). 
The results of examining the potential effects of each flavonoid on the total protein levels 
of CD26 in HT-29 cells treated at low or high confluence levels are shown in Figures 3.7, 3.8, 
3.9, and 3.10. Despite consistent upward trends in averaged data at increasing doses of apigenin 
(Figure 3.7) and numerical increases of mean data of as high as 40%, there were no statistically 
significant findings with respect to the amount of CD26 protein following treatment with any 
concentration of any flavonoid at any confluence level. However, it is apparent that averaged 
data show less elevation from control for the three other flavonoids (Figures 3.8, 3.9, and 3.10) 
than for apigenin (Figure 3.7). 
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Figure 3.7 CD26 protein expression in HT-29 cells treated with apigenin at different 
confluence levels. 
HT-29 cells were treated at low or high confluence with apigenin for 24h at the indicated 
concentrations. Protein fractions were immunoblotted for expression of CD26. β-actin was used 
as a loading control to which the levels of CD26 protein in each sample were normalized. Data is 
presented as mean ± SEM from three independent experiments. Statistical analysis was done 
using two-way ANOVA with Bonferroni’s post-test used to compare the replicate means. 
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Figure 3.8 CD26 protein expression in HT-29 cells treated with genistein at different 
confluence levels. 
HT-29 cells were treated at low or high confluence with genistein for 24h at the indicated 
concentrations. Protein fractions were immunoblotted for expression of CD26. β-actin was used 
as a loading control to which the levels of CD26 protein in each sample were normalized. Data is 
presented as mean ± SEM from three independent experiments. Statistical analysis was done 
using two-way ANOVA with Bonferroni’s post-test used to compare the replicate means. 
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Figure 3.9 CD26 protein expression in HT-29 cells treated with kaempferol at different 
confluence levels. 
HT-29 cells were treated at low or high confluence with kaempferol for 24h at the indicated 
concentrations. Protein fractions were immunoblotted for expression of CD26. β-actin was used 
as a loading control to which the levels of CD26 protein in each sample were normalized. Data is 
presented as mean ± SEM from three independent experiments. Statistical analysis was done 
using two-way ANOVA with Bonferroni’s post-test used to compare the replicate means. 
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Figure 3.10 CD26 protein expression in HT-29 cells treated with luteolin at different 
confluence levels. 
HT-29 cells were treated at low or high confluence with luteolin for 24h at the indicated 
concentrations. Protein fractions were immunoblotted for expression of CD26. β-actin was used 
as a loading control to which the levels of CD26 protein in each sample were normalized. Data is 
presented as mean ± SEM from three independent experiments. Statistical analysis was done 
using two-way ANOVA with Bonferroni’s post-test used to compare the replicate means. 
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3.5 Changes in the Cellular Localization of CD26 in Response to Apigenin 
Given that I found no statistically significant elevations in either CD26 mRNA 
expression or whole cell CD26 protein despite previous laboratory findings of a substantial 
increase in cell-surface CD26 in HT-29 cells after apigenin treatment at these concentrations, it 
was important to consider whether there might be a shift in the cellular localization of CD26 
after treatment with this flavonoid.
15
 
The localization of CD26 protein in HT-29 cells following flavonoid treatment was 
investigated using immunofluorescence microscopy. Based upon previous data the CD26 was 
expected to be predominantly located at the cell surface.
15
 Surprisingly, substantial CD26 was 
found to be located intracellularly (Figure 3.11). This aside, there were substantial changes based 
upon exposure of HT-29 cells to apigenin (100μM) or the degree of confluence (Figure 3.11). 
Apigenin-treated cells at low confluence displayed a greater amount of CD26 
immunoreactivity than vehicle-treated cells, and strong reactivity was found in a significant 
proportion of apigenin-treated cells in circular bodies in the middle of the cells (Figure 3.11, 
panels A, B). In contrast, apigenin-treated cells in high confluence monolayer displayed slightly 
less CD26 protein compared to their correspondent vehicle control and did not show the dramatic 
response seen at low confluence (Figure 3.11, panels C, D). In neither situation of cell density 
was there substantial staining in the area of the plasma membrane as identified with the 
CellMask Deep Red plasma membrane stain. 
The circular bodies in the middle of the cells (e.g. Figure 3.11B) appeared to resemble 
nuclei. It has previously been shown that CD26 may localize in nuclear regions.
95, 122, 123
 I 
therefore wished to examine this further, and to see whether this localization effect could also be 
induced by the flavonoids genistein, kaempferol, and luteolin.  
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The most dramatic appearance in this context (Figure 3.11) was evident with cells at low 
confluence. Therefore HT-29 cells were treated with 60μM apigenin, genistein, kaempferol, or 
luteolin at low confluence and a DAPI stain was used to identify cell nuclei (Figure 3.12). Both 
apigenin- and genistein-treated cells contain greater amounts of CD26 protein in areas which 
coincide with their nuclei as stained with DAPI, compared to vehicle-treated cells (Figure 3.12, 
panels A, B). These effects were not observed in kaempferol- and luteolin-treated cells (Figure 
3.12, panels C,D). Cells treated with kaempferol or luteolin instead showed a slight decrease in 
CD26 staining compared to vehicle-treated cells (Figure 3.12, panel E). 
Although seeming to be nuclei, there is a possibility that the CD26-rich areas are instead 
structures which overlay or surround the nucleus, such as the endoplasmic reticulum or the Golgi 
apparatus. Interestingly in this approach the nuclei of apigenin- and genistein-treated cells were 
also smaller and the nuclear material was more condensed (Figure 3.12, panels A, B). However, 
this had not been the case with apigenin treatment in Figure 3.11 (panel B). 
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Figure 3.11. CD26 visualized in apigenin-treated HT-29 cells at different confluence levels 
by confocal microscopy. 
HT-29 cells were treated with (A, C) vehicle control or (B, D) 100μM apigenin for 24h. They 
were stained with CD26 primary antibody, anti-rabbit AlexaFluor 488 secondary antibody, and a 
CellMask Deep Red plasma membrane stain. Images of areas at low (A, B) or high (C, D) 
confluence are shown. Images shown are representative of two independent experiments. 
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Figure 3.12. CD26 visualized in HT-29 cells treated with apigenin, genistein, kaempferol, or 
luteolin at a low level of confluence by fluorescence microscopy. 
HT-29 cells were treated with 60μM (A) apigenin, (B) genistein, (C) kaempferol, or (D) luteolin, 
relative to (E) vehicle control for 24h .They were stained with CD26 primary antibody and anti-
rabbit AlexaFluor 488 (green) secondary antibody. Afterwards they were stained using DAPI 
(blue) to visualize nuclei. Images shown are representative of three independent experiments. 
  
C 
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4 Discussion 
4.1 Overview 
 The data collected during this project demonstrate the effects - or lack thereof - of 
flavonoids on three key cell-surface enzymes associated with the development of colon cancer.  
First, HT-29 colorectal carcinoma cells cultured to different levels of confluence were 
treated with apigenin to determine whether this would affect the mRNA transcription of CD26, 
CD38, and CD73. Finding that the levels of mRNA for CD38 and CD73 showed no observable 
change in response to this key flavonoid, CD26 was selected as the focus of subsequent 
experimental work. 
Focusing then on CD26, three flavonoids similar to apigenin in both chemical structure 
and biological function were also used in the further experiments: genistein, kaempferol, and 
luteolin. The mRNA transcription, protein quantity, and protein localization of CD26 were 
investigated in HT-29 cells treated with the four flavonoids at different confluence levels. 
Although there was no significant change in mRNA transcription or total whole cell 
protein, I found clear evidence for a shift in the cellular localization of CD26 in response to two 
of the flavonoids. There appeared to be an increase in the nuclear localization of CD26 protein in 
cells treated at low confluence with 60μM apigenin or genistein. This data both complements and 
contrasts with that of Lefort and Blay, whose work showed that a 24h 30μM apigenin treatment 
significantly upregulated the cell-surface CD26 levels in HT-29 cells.
15
 
4.2 Target Identification  
 The enzymes CD26, CD38 and CD73 are all relevant to the development and progression 
of colorectal cancer although their precise roles within this context remain to be elucidated.
70-72, 
108, 109, 124
 Using end-point PCR in conjunction with agarose gel electrophoresis, the presence of 
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CD26, CD38 and CD73 mRNA was detected in HT-29 colon cancer cells, suggesting that the 
corresponding protein is also produced in this cell line.
125
 I focused on whether the mRNA 
quantities of these enzymes could be modulated by apigenin treatment, and, if so, whether this 
effect was dependent on cell confluence. In comparison with vehicle-treated control cells, the 
levels of CD26 mRNA appeared to increase only in apigenin-treated cells harvested at 90% and 
100% confluence. CD38 mRNA levels appeared to increase somewhat but only in apigenin-
treated cells collected at 100% confluence. The amount of CD73 mRNA did not change 
following apigenin treatment regardless of the confluence level of the cells at the time of RNA 
collection. CD26 was chosen as the most promising target on which to focus. Moreover the 
putative shifts in CD26 mRNA levels appeared to depend on cell confluence. Therefore I 
predicted that the abundance of CD26 protein would be modulated by both flavonoid treatment 
and cell density. 
4.3 Flavonoid Cytotoxicity 
 The flavonoids genistein, kaempferol, and luteolin were chosen for this study as they are 
structurally and functionally very similar to apigenin. They may have comparable effects but in 
the case of changes in CD26 may function differently.
11, 35-49
 Lefort and Blay found that 
treatment with genistein increased cell-surface CD26 in HT-29 cells similarly to apigenin albeit 
to a lesser degree.
15
 They also found that kaempferol treatment had no effect on cell-surface 
CD26.
15
 Kaempferol was included in this project for this reason - essentially as a control - but 
also because it shares the cytosolic effects induced by apigenin, genistein, and luteolin (see 
Tables 1.1, 1.2, and 1.3). Luteolin is a bioactive flavonoid in its own right and also the primary 
metabolite of apigenin. 
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The cytotoxicity of these flavonoids to HT-29 cells needed to be determined such that 
only subtoxic concentrations would be used throughout the remainder of this project. In this way, 
any results obtained would not be confounded by any cytotoxic cell processes these substances 
may have induced. Although the cytotoxicity of apigenin, genistein, kaempferol, and luteolin has 
been previously studied in other laboratories, changes to cell culture conditions such as the 
media type or oxygen concentration can change the chemosensitivity of cancer cells.
126, 127
 
Therefore MTT assays were used to determine the cytotoxicity of the four flavonoids in HT-29 
cells under the conditions used in this study. 
 It was found that neither apigenin, genistein, nor kaempferol induced significant 
cytotoxicity at any of the concentrations used over the 24h treatment period. However, 100μM 
luteolin decreased cell viability by 20% and this was statistically significant. The second highest 
treatment, 60μM, was chosen as the usual maximal flavonoid concentration to be used in this 
project because it did not induce any cytotoxicity for any of the flavonoids tested.  
Curiously, cells treated with 3μM and 10μM luteolin appeared to experience an increase 
in mitochondrial activity - up to 10% - and this effect was found to be statistically significant for 
the luteolin treatments. This phenomenon may also be biologically significant because it may 
indicate an increase in cell growth. Several studies have shown that genistein stimulates cell 
growth at concentrations under 10μM in breast and cervical cancer cell lines.128-131 Genistein, a 
phytoestrogen, can induce cell proliferation at low concentrations by acting as an estrogen 
receptor agonist.
128-131
 Indeed, this effect has led some to suggest that dietary genistein may not 
be safe for postmenopausal women with estrogen dependent breast cancers.
132
 Estrogen receptors 
are present within the colonic epithelium and several studies show that their expression is 
decreased in colorectal cancer tissues compared to normal epithelium.
133-135
 The mRNA of 
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estrogen receptor β (ERβ) has been found in the HT-29 cell line although it is as yet unknown 
whether these cells express ERβ protein.136 Being that genistein is the most estrogenic flavonoid 
and ubiquitous in the diet, it is the focus of most flavonoid estrogenicity studies.
137
 Luteolin and 
apigenin are estimated to have 58% and 16% of the estrogenic activity of genistein, 
respectively.
137
 The estrogenic potential of kaempferol is estimated to be equal to or slightly less 
than that of apigenin.
138
 If a biologically significant proliferative effect occurred, it is likely that 
it was mediated by estrogen receptors; this would explain why it was observed in cells treated 
with luteolin but not in those treated with apigenin or kaempferol. However, it remains curious 
that the same effect was not observed in genistein-treated cells.   
Because the 30μM treatments neither inhibited nor stimulated cell viability, this 
concentration was chosen as the second subtoxic flavonoid treatment to be used in this project. 
4.4 Quantifying CD26 mRNA Transcription 
 Next, changes in the transcription of CD26 mRNA were quantified using qPCR. Using 
24h treatments of either 30μM or 60μM flavonoids, cells were treated at 50% (low) or 100% 
(high) confluence. There were no statistically significant findings or relationships between the 
flavonoid used, flavonoid concentrations, and cell confluence levels.  
In contrast to the results observed in the end-point PCR experiments, the amount of 
CD26 mRNA appeared to decrease following the treatment of low confluence cells with any 
concentration of apigenin.  
The lack of statistically significant findings from the mRNA data could be attributed to 
the high degree of variability often found with cancer cells. A study of human breast, liver, lung, 
and colon cancer tissues found that roughly 75% of genes had increased data variances compared 
to adjacent normal tissues.
139
 These variances in mRNA expression, dubbed “noise”, have been 
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observed and their potential origins discussed in a number of studies.
140-144
 Even within a 
population of identical cells, such noise occurs and can be attributed to the inherent 
“stochasticity”, or randomness, of the chemical reactions involved within biological 
processes.
140, 141
 Other relevant factors include the location of the gene in question, the rate of 
mRNA degradation, and cell doubling time.
142
 Indeed, yeast cells exhibit more gene expression 
noise at lower growth rates and within environmentally-regulated genes which are not otherwise 
constitutively expressed.
143
 Because CD26 is not constitutively expressed or explicitly required 
for a cell’s survival, one could expect its transcription to exhibit a greater degree of noise. 
However, it is possible that the actions of the flavonoids themselves within the HT-29 cells 
contributed to the high degree of variance in the mRNA expression levels. As previously 
discussed, flavonoids exert myriad epigenetic effects including histone acetylation. Histone 
modifications have been hypothesized to be a source of genetic noise.
144
 In the future, absolute 
quantification of CD26 mRNA within HT-29 cells could determine whether the transcription of 
CD26 has an inherently high degree of noise and whether this could be further modulated 
following flavonoid treatment.  
4.5 Quantifying CD26 Protein 
 The amount of whole-cell CD26 protein in HT-29 cells was then quantified to observe 
whether the flavonoid-induced increases in cell-surface CD26 protein discovered by Lefort and 
Blay originated as a result of an increase in the production of functional CD26 protein, 
irrespective of the magnitude of any change in CD26 mRNA.
15
 There were no significant 
differences in the amount of CD26 protein between cells treated with any concentration of the 
four selected flavonoids, at any level of confluence.  
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While protein quantities are primarily determined by the amount of mRNA present when 
cells are in a “steady state”, post-transcriptional processes play a significant role in short-term 
adaptations to changes in the environment.
145
 Whether an increase in translation or targeted 
breakdown via ubiquitination, these processes can quickly regulate the amount of protein in the 
cell and may also determine the levels of CD26 protein after cellular exposure to flavonoids.
145
 
Post-translational modifications are also involved, including those that may target the protein for 
transport.
145
 Although the protein levels of CD26 were not significantly altered following 
flavonoid treatment, it is possible that the CD26 protein was modified post-translationally such 
that it was targeted to the apical surface of the plasma membrane in the HT-29 cells. This may 
explain the results found by Lefort and Blay.  
 Although not statistically significant, apigenin treatment appears to suggest a slight 
upregulation in the levels of CD26 protein in both low and high confluence cells. This compares 
with the trend observed by Lefort and Blay in which apigenin treatment produced a significant 
upregulation of cell-surface CD26 in HT-29 cells.
15
 It is possible that the effect observed by 
Lefort and Blay is produced by the upregulation of whole cell CD26 protein in conjunction with 
an increased transport of CD26 to the surface of the cell. Of note is the observation that low 
confluence cells appeared to experience a greater upregulation of CD26 upon treatment with 
apigenin than high confluence cells. This suggests that cell confluence may affect the degree of 
the cellular response to apigenin treatment.  
 Cells treated with genistein at low confluence also appeared to experience an 
upregulation of CD26 protein, although this upregulation appeared to occur to a lesser degree 
than it did in apigenin-treated cells. This also follows the trends observed by Lefort and Blay, in 
which genistein treatment increased the levels of cell-surface CD26 to a lesser degree than did 
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apigenin treatment. However, high confluence cells treated with genistein appeared to experience 
a downregulation of CD26 protein compared to vehicle-treated control, with the 30μM 
concentration appearing to produce this effect to a greater degree.  
The levels of CD26 protein found in cells treated with either kaempferol or luteolin 
appear to be very similar to those found in control cells. With respect to kaempferol, this was 
expected; Lefort and Blay found that it had no effect on the levels of cell-surface CD26. 
4.6 Visualizing CD26 Protein 
  Finally, the localization of intracellular CD26 protein was visualized using 
immunofluorescence microscopy.  
 In the first such experiment, HT-29 cells were treated with 100μM apigenin, a 
concentration which was not found to be cytotoxic in this cell line. Populations of cells 
throughout each well were found at different levels of confluence. Vehicle-treated cells 
displayed a small amount of CD26 evenly distributed throughout each cell, regardless of 
confluence level. Cells treated with apigenin at high confluence displayed CD26 in a similar 
fashion. However, cells treated at low confluence were markedly different. Round structures in 
the middle of the cells became apparent and were significantly brighter than the CD26 staining 
observed in the control cells. These results follow the pattern observed in the western 
immunoblots: CD26 protein levels were more susceptible to apigenin treatment in low 
confluence cells than in high confluence cells. The bright and circular CD26 staining patterns 
were enclosed within the confines delineated by the CellMask Deep Red plasma membrane stain, 
suggesting that these were cytosolic structures. It was believed that these were the cell nuclei 
although this could not yet be confirmed without using a nuclear stain. Both the confluent and 
subconfluent cell populations imaged in this experiment had been cultured together within the 
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same well, meaning that the environmental conditions to which these cells had been exposed 
were identical. Having observed markedly different patterns in CD26 staining in these two cell 
subpopulations, this reinforced the idea that confluence was a determining factor in the cellular 
response to apigenin treatment.  
In order to confirm whether the round structures previously seen were indeed nuclei, the 
experiment was repeated using a DAPI nuclear stain. This time, 60μM treatments - the highest 
subtoxic concentration - of each of the four flavonoids were compared. Furthermore, only those 
subpopulations of cells which had reached a low level of confluence were imaged so as to more 
clearly investigate the results produced in the previous immunofluorescence experiment. 
In this experiment, apigenin- and genistein-treated cells displayed markedly brighter 
areas which overlapped their nuclei compared to control cells. This was attributed to increased 
nuclear CD26 staining. In contrast to the results found by Lefort and Blay, however, there did 
not appear to be an increase in plasma membrane CD26 staining. Kaempferol- and luteolin- 
treated cells did not exhibit such nuclear CD26 staining, and even appeared to have slightly less 
CD26 than did the vehicle-treated control cells.  
 The role of nuclear CD26 has not been well characterized in the literature although its 
translocation to the nucleus has been found to occur in response to treatment with anti-CD26 
antibodies.
95, 122
 If this phenomenon had occurred in these experiments, nuclear CD26 would 
have been found in every treatment group and the vehicle-treated control as well. This was not 
the case, however, so it can be inferred that treatment with apigenin and genistein must have 
caused this localization. Indeed, even Yamada et al. found that only one of the two antibodies 
they used induced the nuclear translocation of CD26.
122
 This suggests that this effect requires 
that a ligand binds a specific epitope on the CD26 protein.
122
 Yamada et al. also found that CD26 
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is translocated into the nucleus using caveolin-dependent endocytosis.
95
 It is likely that this 
phenomenon occurred in the apigenin- and genistein-treated HT-29 cells as well. Given that the 
levels of CD26 mRNA and protein levels were not significantly altered, a translocation of CD26 
is the most probable explanation for the increase in CD26 protein observed in the area of the 
nucleus. Yamada et al. observed that nuclear CD26 interacted with the POLR2A gene and 
repressed the transcription of its gene product, a subunit of RNA polymerase II.
95
 In turn this 
reduced the cellular proliferation of the cancer cells used.
95
 Although there is nothing to suggest 
that this is what occurred in the HT-29 cells, it remains a possibility considering that apigenin 
and genistein are both known to hinder cellular proliferation in this cell line. 
Apigenin and genistein are isomers as are kaempferol and luteolin. The latter two have an 
additional hydroxyl group compared to the former two and this makes them more hydrophilic. It 
is possible that the molecular structure of apigenin and genistein allowed these substances to 
bind CD26 in such a way that it translocated to the nucleus. In addition, it is also possible that, 
being more lipophilic than kaempferol or luteolin, they penetrated the plasma membrane more 
easily and could therefore bind the epitope of CD26 and induce its nuclear translocation.  
 It is important to note that not every cell nucleus displayed CD26. Generally, the nuclei 
in which CD26 was abundant were the ones which had shrunk the most. This may indicate that 
there is a subpopulation of cells which are more susceptible to the effects of apigenin and 
genistein treatment on the localization of CD26 protein. Since cancer cells are, by definition, 
genomically unstable, genetic and phenotypic cell heterogeneity has been identified in numerous 
cancer cell lines including the colorectal carcinoma lines Caco-2 and HT-29.
146-150
   
One might argue that the nuclear shrinking observed is actually evidence of an apoptotic 
process in which chromatin is condensed, fragmented, and subsequently destroyed.
151
 This 
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nuclear shrinking is comprised of three stages, each of which are morphologically distinct and 
which altogether last 30-45min.
151
 In the first stage, a continuous ring of condensed chromatin 
appears within the nucleus, and this ring becomes progressively more beaded and discontinuous 
in appearance as the second stage begins and the nucleus begins to shrink.
151
 This step only lasts 
for 15-30min before the nucleus has become entirely fragmented.
151
 Indeed, the annulus which 
characterizes the second stage can be seen in the form of circles within the nuclei of the 
apigenin- and genistein-treated cells. However, these banding patterns come from the green 
CD26 antibody and not from the blue DAPI stain. Because DAPI binds DNA directly, one would 
expect the banding patterns to come from the blue DAPI stain binding the condensed chromatin 
ring. Furthermore, the banding patterns observed in the HT-29 cells are different from those 
observed by Toné et al. because they occupy a greater proportion of the nucleus.
151
 Lastly, 
similar banding patterns can be observed in the low-confluence HT-29 cells which had been 
treated with 100μM apigenin. These cells were not treated with any nuclear stain and yet these 
banding patterns are visible in regions bound by CD26 antibody. As previously mentioned, it is 
possible that CD26 is in the nucleus to repress (or perhaps induce) a transcriptional event. Any 
CD26-independent transcriptional or epigenetic effects induced by flavonoid treatment would 
have also been observed in kaempferol- and luteolin-treated cells.  
4.7 Limitations and Future Directions  
 Although all colorectal cancers produce similar and predictable symptoms, colorectal 
cancers are actually a heterogeneous group of diseases with multiple genetically distinct 
subtypes.
152, 153
 Therefore the results obtained using a single colorectal cancer cell line cannot be 
generalized to other cell lines. Neither can they be generalized to colorectal cancer in situ. This is 
further evidenced by the fact that experiments using cultured cells, as with any other in vitro 
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tumor model, observe the behaviour of these cells in isolation and not necessarily as they would 
exist in vivo under physiological conditions.
154
  
In terms of further elucidation of events observed here, first it must be confirmed whether 
a caveolin-dependent endocytotic translocation of CD26 is what occurred following treatment 
with apigenin and genistein; this can be done by simultaneously treating the cells with an 
endocytosis inhibitor. Next, the activity of CD26 in the cell nucleus and its significance with 
respect to cell activity must be elucidated. This work must then be continued using other 
colorectal cancer cell lines to establish the presence of CD26 and determine whether its 
translocation to the nucleus is similarly induced following treatment with apigenin or genistein.  
If any sufficiently significant result were to be obtained following such more thorough 
explanation of the treatment of cancer cells with flavonoids, it would be difficult to make any 
conclusions regarding the normal dietary consumption of these substances. As previously 
mentioned, most epidemiological data gathered on flavonoids is with regard to genistein simply 
uses information based on their ubiquity in the human diet. Given the structural similarity of 
genistein to the other flavonoids, one could expect that they are metabolized in similar ways. The 
quantity of flavonoids consumed can vary greatly depending on one’s location and diet. Even 
within raw soybeans, known to be rich in flavonoids, the flavonoid content ranges between 18 to 
562 mg/100g due to myriad environmental factors.
155
 Ethnic origin of the subject, age, gut transit 
time, individual flavonoid metabolism phenotypes, and the plant source of the flavonoids also 
greatly affect their bioavailability in the blood plasma.
156-159
 Furthermore, the flavonoid 
concentrations used in many studies, including this one, are much greater than what is naturally 
found in human blood plasma. Therefore new delivery methods, such as liposome encapsulation, 
are under development to enhance flavonoid bioavailability.
160
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6 Appendix 
 
RIPA Buffer 
NaCl 150mM 
Tris-HCl 50mM 
Triton X-100 1% 
Na-Deoxycholate 0.5% 
SDS 0.1% 
EDTA 1mM 
Aprotinin 1μg/mL 
Leupeptin 5μg/mL 
Phenylmethylsulfonylfluoride 1mM 
Ethylenediaminetetraacetic acid 5mM 
MilliQ H2O  
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pH 7.4  
 
Polyacrylamde Resolving Gel  
Tris-HCl, pH 8.8 0.4M 
Acrylamide/bisacrylamide 8% 
SDS 0.1% 
Ammonium Persulfate 0.05% 
TEMED 7% 
MilliQ H2O  
 
Polyacrylamide Stacking Gel 
Tris-HCl, pH 6.8 0.13M 
Acrylamide/bisacrylamide 4% 
SDS 0.1% 
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Ammonium Persulfate 0.05% 
TEMED 0.1% 
MilliQ H2O  
 
Running Buffer 
SDS 0.1% 
Glycine 192mM 
Tris Base 25mM 
Methanol 20% 
MilliQ H2O  
 
Transfer Buffer  
Glycine 192mM 
Tris Base 25mM 
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Methanol 20% 
MilliQ H2O  
 
TBS-T 
Tris Base 50mM 
NaCl 150mM 
Tween-20 0.1% 
MilliQ H2O  
pH 7.6  
 
1% PFA 
PFA 1% 
MilliQ H2O  
 
 
 
87 
 
PBS 
NaCl 0.8% 
KCl 0.02% 
Na2HPO4 0.115% 
KH2PO4 0.02% 
MilliQ H2O  
 
PBS Ca
2+
/ Mg
2+
 
NaCl 0.8% 
KCl 0.02% 
Na2HPO4 0.115% 
KH2PO4 0.02% 
CaCl2 • 2H2O 0.0132% 
MgCl2 • 6H2O 0.01% 
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MilliQ H2O  
 
2x Laemmli Sample Buffer 
Tris-HCl pH 6.8 0.5M 
Glycerol 10% 
SDS 2% 
2-β-Mercaptoethanol 5% 
Bromophenol Blue  0.01% 
MilliQ H2O  
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Chemiluminescent Solution 
Hydrogen Peroxide 0.01% 
Luminol 1.25mM 
p-Coumaric Acid 0.2mM 
Tris-HCl pH 8.5  
 
